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AND HUMAN DISEASE
Supawat Thongthip, Ph.D.
The Rockefeller University 2017

DNA interstrand crosslink (ICL) repair is vital for cellular proliferation and
survival. Defects in the repair of DNA crosslinks have been associated with
congenital abnormalities, bone marrow and kidney failure, liver dysfunction, and
cancer. DNA nucleases play a significant role during the repair of ICLs and they
function at multiple repair steps. Here, we assessed the contributions of
FANCD2/FANCI-Associated Nuclease 1 (FAN1) to the repair of ICL lesions and
studied the consequences of its deficiency, which results in rare chronic kidney
disease - Karyomegalic Interstitial Nephritis (KIN). FAN1 is a highly conserved
nuclease from yeast to humans. It was first identified in an RNAi screen for
proteins necessary for ICL repair and also as a direct interacting partner of
FANCI/FANCD2 (ID2) complex of the Fanconi anemia pathway. Using cells
isolated from human KIN patients and Fan1-deficient mice, we showed that ICL
repair function of FAN1 is non-overlapping with Fanconi anemia proteins, yet
redundant with SNM1A, an exonuclease that was previously implicated in ICL

repair. Furthermore, the Fan1 knockout mouse model recapitulates many of the
phenotypes observed in human KIN patients, including renal karyomegaly and
liver dysfunction. Fan1-deficient mice displayed hypersensitivity to ICL-inducing
chemotherapeutic drugs and developed bone marrow failure following the
treatment. We also demonstrated that formaldehyde and acetaldehyde are likely
not the endogenous damaging agents that lead to KIN in the absence of FAN1.
In parallel studies, we explored the possibility of rescuing ICL sensitivity of
Fanconi anemia patient cells through an inhibition of non-homologous end joining
repair (NHEJ) factors. Using both genetic and chemical approaches, we showed
that NHEJ suppression could not compensate for the lack of FA pathway in the
repair of ICLs.
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Chapter 1: Introduction
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1.1 Types and sources of DNA damage
The maintenance of genomic stability is necessary to allow the faithful
transmission of the genetic information across generations. To preserve genomic
integrity, DNA must be protected from damage generated spontaneously during
DNA transactions or inflicted by environmental agents (Ciccia and Elledge, 2010).
The spontaneous lesions can arise as a result of the nucleotide misincorporation
during DNA replication, DNA base interconversions by DNA deamination or the
loss of DNA bases by DNA depurination (Lindahl, 1993; Lindahl and Barnes,
2000). The environment is another important source of DNA damage. One of the
most deleterious type of DNA damaging agents is ionizing radiation (IR) from xray or g-ray that can induce DNA single strand breaks (SSBs) and DNA double
strand breaks (DSBs). More frequently in everyday life, exposure to ultraviolet
(UV) light leads to the formation of DNA-pyrimidine dimers and 6-4 photoadducts which can account for 105 DNA lesions per day (Hoeijmakers, 2009).
Additionally, inside the cell, DNA is frequently struck by reactive oxygen species
(ROS), which can damage DNA bases and result in DNA breaks (Hoeijmakers,
2009).

The type of DNA damage that this thesis is concerned with is DNA
interstrand crosslink (ICL) damage. DNA ICLs are lesions that form when the
bases from opposite strands of DNA are linked together through a covalent bond.
ICLs are detrimental to cells due to their ability to prevent separation of DNA
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double helices, therefore interfering with processes such as DNA replication and
transcription. ICLs can be induced by many of the front-line chemotherapeutic
drugs

including

nitrogen

mustard

derivatives

such

as

melphalan

and

cyclophosphamide, platinum-based compounds such as cisplatin and carboplatin,
mitomycin C (MMC), and psoralen (Deans and West, 2011; Dunnick et al., 1987;
Eastman, 1983; Gargiulo et al., 1995; Goodman et al., 1946). Additionally, ICLs
can also be induced by molecules made within cells (Clauson et al., 2013).
Recent studies have implicated aldehydes as well as the oxidized DNA bases
and nitric oxide as their potential sources (Clauson et al., 2013; Garaycoechea et
al., 2012; Langevin et al., 2011; Pontel et al., 2015). Reactive aldehydes such as
formaldehyde, acetaldehyde, malondialdehyde and acrolein have been shown in
vitro and in vivo to be potent DNA crosslinkers (Kirchner et al., 1992; McGhee
and von Hippel, 1977; Stein et al., 2006; Stone et al., 2008). Deficiency in the
repair of ICLs has been associated with

human genetic diseases Fanconi

anemia and Karyomegalic Interstitial Nephritis (KIN) (reviewed in (Kottemann
and Smogorzewska, 2013; Moldovan and D’Andrea, 2009).

1.2 Fanconi anemia
Fanconi anemia (FA) is a rare genetic disease that occurs in about 1 in
every 100,000 births. It is characterized by congenital abnormalities, bone
marrow failure and predisposition to blood and solid cancers (Alter, 2003;
Butturini et al., 1994; Fanconi, 1967; Schmid and Fanconi, 1978). FA patients
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display cellular hypersensitivity to ICL inducing agents such as mitomycin C
(MMC) and diepoxybutane (DEB), which results in increased cell death and
characteristic

chromosomal

abnormalities

including

radial

chromosomes

(Auerbach et al., 1989; Scharer, 2005). Fanconi anemia disorder is genetically
heterogeneous. At present, 21 genes have been found to be mutated in Fanconi
anemia or Fanconi anemia-like patients. All of the identified mutated genes have
been assigned a name as “FANC” genes, including FANCA, B, C, D1, D2, E, F,
G, I, J, L, M, N, O, P, Q, R, S, T, U, and V. To date, there remain some patients
whose complementation groups have not been assigned (Bluteau et al., 2016;
Ceccaldi et al., 2016; Park et al., 2016).

FA patients are born with a range of birth defects including short stature,
microcephaly, the absence of radius and thumbs, pigmentation defects,
abnormalities of the cardiovascular, gastro-intestinal, and urinary systems
(Auerbach,

2009;

Shimamura

and

Alter,

2010).

The

developmental

malformations can vary between patients and complementation groups. FA
patients with complementation group D1, J and N display more severe congenital
abnormalities than others (Levran et al., 2005; Reid et al., 2007; Wagner et al.,
2004). In addition, infertility is almost universal, with almost none of the male
patients being reported to have offspring and the affected females developing
menopause at much earlier age (Auerbach, 2009). However, the most common
phenotype shared among FA patients is pancytopenia caused by progressive
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bone marrow failure (Auerbach, 2009; Kutler et al., 2003b). FA patients are also
presented with a high risk of developing blood malignancies such as
myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) due to bone
marrow abnormalities (Alter et al., 2010; Rosenberg et al., 2003).

Bone marrow failure is driven by dysfunctional hematopoietic stem cells
(HSCs) and progenitor cells due to recurrent DNA damage-activated apoptosis.
Disruption of FA pathway leads to elevated DNA damage in the HSCs, which in
turn promotes activation of p53- and p21-mediated programmed cell death or cell
cycle arrest (Ceccaldi et al., 2012; Tulpule et al., 2010). FA patients are born with
lower levels of HSCs, which display lower proliferative potential and reduced
repopulating and differentiating abilities (Ceccaldi et al., 2012; Kelly et al., 2007).
Furthermore, exposure of hematopoietic progenitor cells to crosslinking agents
intensifies their proliferation deficiency (Vinciguerra et al., 2010). These findings
suggest that the FA pathway is required for the protection of hematopoietic stem
cells from accumulating ICLs.

Defective DNA repair in FA cells can lead to mutations and genomic
instability, which promotes tumorigenesis. In addition to blood malignancy
mentioned before, FA patients are at a high risk of developing solid tumors,
including several hundred-fold increase in risk of head and neck squamous cell
carcinoma over that present in the general population (Kutler et al., 2003a;
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Rosenberg et al., 2003). A number of FA genes, which encode proteins
participating in homology-directed repair including FANCD1 (BRCA2), FANCJ
(BRIP1) and FANCN (PALB2) are breast and ovarian cancer susceptibility genes.
This association demonstrates a close link between the Fanconi anemia pathway
and tumor suppression (Deans and West, 2011; Rafnar et al., 2011; Rahman et
al., 2007; Seal et al., 2006; Shah et al., 2013; Tischkowitz et al., 2007; Walsh et
al., 2011).

1.3 Fanconi anemia proteins and ICL repair
The products of FANC genes – “Fanconi anemia (FA) proteins” are
necessary for the repair of ICLs. They participate in identification of the lesion
and activation of repair, nucleolytic processing of the crosslink, translesion
synthesis (TLS) against an unhooked lesion, and homologous recombination
(HR) (Figure 1.1A-D) (reviewed in (Ceccaldi et al., 2016; Kottemann and
Smogorzewska, 2013). The role of FA proteins in ICL repair has been
extensively studied using mammalian cells, Xenopus egg extracts, and the in
vitro biochemical analysis. In the current model derived from these studies, the
FA core complex proteins (A, B, C, E, F, G, L and M) and the associated proteins
are involved in detection of the damage. Upon the recognition of the crosslink,
FANCL, an E3 ubiquitin ligase of the FA core complex, aided by E2 ubiquitinconjugating enzyme, FANCT/UBE2T, monoubiquitinate FANCD2 and FANCI
(Figure 1.1A) (reviewed in (Ceccaldi et al., 2016; Walden and Deans, 2014).
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FANCD2 and FANCI are paralogs that can heterodimerize to form the ID2
complex. The dynamic association and localization of FANCI/FANCD2 are
influenced by their ubiquitination status. Human FANCD2 and FANCI are
monoubiquitinated at residue K561 and K523 respectively (Garcia-Higuera et al.,
2001; Montes de Oca et al., 2005; Smogorzewska et al., 2007). The
monoubiquitination of FANCD2 and FANCI are essential for the ICL repair
function of the FA pathway (Smogorzewska et al., 2007). Additionally,
phosphorylation of FANCI by ATR provides a crucial regulatory mechanism of
the repair pathway (Ishiai et al., 2008; Wang, 2008).

The function of the

ubiquitinated ID2 complex is not fully understood. However, it has been shown
to be required for the unhooking of the crosslink and for translesion synthesismediated bypass of the lesion in the Xenopus egg extract system (Figure 1.1B,
C) (Douwel et al., 2014; Knipscheer et al., 2009; Raschle et al., 2008).

The DNA incisions around the ICL require SLX4 (FANCP), a Fanconi
anemia protein that is associated with three structure specific nucleases,
including XPF–ERCC1, MUS81–EME1 and SLX1 (Douwel et al., 2014; Fekairi et
al., 2009; Munoz et al., 2009; Svendsen et al., 2009). SLX4/FANCP is a scaffold
protein that can localize and modulate the activity of its associated nucleases at
the site of damage (Fekairi et al., 2009; Hodskinson et al., 2014; Munoz et al.,
2009; Svendsen et al., 2009; Wyatt et al., 2017). In human cells, the interaction
of SLX4 with MUS81–EME1 and SLX1 are important for the Holliday junctions
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(HJs) resolution during homologous recombination (Garner et al., 2013; Kim et
al., 2013; Svendsen et al., 2009; Wyatt et al., 2013). In contrast, the association
between SLX4 and XPF/FANCQ -ERCC1 have been shown to be essential for
ICL resistance and crosslink unhooking (Crossan et al., 2011; Douwel et al.,
2014; Kim et al., 2011; Kim et al., 2013; Yamamoto et al., 2011). When in
complex with SLX4 in vitro, XPF is found to be able to completely unhook the
crosslink substrates (Hodskinson et al., 2014).

A useful working model of the ICL repair has been proposed based on the
study in the Xenopus egg extracts. According to the model, SLX4 and XPF can
be recruited to the crosslink substrates upon the monoubiquitination of FANCD2
(Figure 1.1B) (Douwel et al., 2014). In this model, repair begins when two of the
replication forks converge at the ICL. Once one of the leading strands arrives
within 1 nucleotide of the ICL, the opposite parental strand can be incised on
either side of the crosslink, resulting in the unhooking of the ICL (Raschle et al.,
2008; reviewed in (Zhang and Walter, 2014). To date, XPF-ERCC1 is the only
nuclease known to be indispensable for the incision event in the Xenopus egg
extracts system (Douwel et al., 2014).

The dual fork convergence model was recently challenged by an in vivo
study from the Seidman lab using DNA-fiber based approach with fluorescentlytagged ICLs (Huang et al., 2013). Seidman and colleagues showed that the
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majority of replications forks can traverse (bypass) the crosslinks without prior
ICL unhooking. Replication traverse of ICLs requires the DNA translocase activity
of FANCM, but not other Fanconi anemia proteins. When replication transverse
is blocked under FANCM deficient setting, the frequency of stalled single fork
collisions with ICLs go up, suggesting that single fork collision precedes
replication traverse. These results indicate that, in mammalian cells, ICLs are
mostly approached by single forks rather than converging dual forks as opposed
to the models proposed by the Xenopus studies. The questions of how FANCM
facilitates replication traverse and the identity of DNA translocase distal to the
ICL remain a subject of further investigation. Nevertheless, Walter and
colleagues argue that, regardless of either models, both dual fork convergence
and replication traverse lead to the formation of X-shape structures at ICLs,
which can be recognized and processed by ICL repair nucleases such as XPFERCC1 (Zhang and Walter, 2014).

Following the incision, the last steps of ICL repair involve translesion
synthesis and homology directed repair. The unhooked base is bypassed by
translesion DNA polymerase whose identity remains unknown before being
extended further by DNA polymerase z (REV3/REV7) (Figure 1.1C) (Raschle et
al., 2008). Concurrently, the double strand break generated by ICL unhooking is
repaired by homology-directed repair, a step which is facilitated by a number of
FA proteins including FANCD1 (BRCA2), FANCJ (BRIP1) and FANCN (PALB2),
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FANCO (RAD51C), FANCP (SLX4), FANCR (RAD51) and FANCS (BRCA1)
(Figure 1.1D) (reviewed in (Ceccaldi et al., 2016; Long et al., 2011; Walden and
Deans, 2014).

Although the FA pathway plays an important role in ICL repair and human
and mouse cells lacking the FA proteins are very sensitive to ICL-inducing
agents, alternative ICL repair mechanisms do exist. ICL repair studies in nonreplicating Xenopus egg extracts revealed the ICL repair pathway that depends
on translesion synthesis polymerase Pol k but not the Fanconi anemia proteins
(Williams et al., 2012). This pathway of ICL repair is thought to be important for
the repair of ICL damage in quiescent or slowly cycling cells that are mainly in
G0/G1 phases of the cell cycle. More recently, a replication-dependent repair
pathway that involves a DNA glycosylase - NEIL3 has been shown to be able to
bypass the need for FA proteins (Semlow et al., 2016). Unlike nuclease-mediated
ICL unhooking, NEIL3 directly cleaves the N-glycosyl bond without damaging the
sugar phosphate backbone and functions independently of FANCI-FANCD2.
NEIL3-mediated unhooking has been shown to be a major pathway for the repair
of psoralen and abasic (AP) site ICLs. Following the cleavage of N-glycosyl bond,
gaps are filled in by TLS polymerases. The significance of NEIL3-ICL repair
pathway in vivo remains unclear as unhooking can still proceed via FANCIFANCD2-dependent incisions when N-glycosyl bond cleavage is prevented,
(Semlow et al., 2016).
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Figure 1.1 Model of the Fanconi anemia DNA repair pathway.
(A) Upon the detection of ICL damage, ATR phosphorylates multiple repair
proteins. This together with the monoubiquitination of FANCI and FANCD2
of the ID2 complex by the Fanconi anemia (FA) core complex lead to the
activation of the FA pathway. (B) ID2 complex is thought to coordinate DNA
nucleases during ICL incision. (C-D) The unhooked intermediates are
repaired by translesion synthesis (C) and homologous recombination (HR)
(D). HR proteins are also required for the protection of the replication forks
earlier during repair.
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1.4 The identification of FANCD2/FANCI interacting protein: FAN1
The mechanism of how monoubiquitinated ID2 complex provides a
platform for DNA nucleases or translesion synthesis polymerases for ICL
processing remains unclear. Multiple studies arrived at one possible effector of
the

ID2

complex

nuclease 1)

function,

KIAA1018/FAN1

(FANCD2/FANCI-associated

(Kratz et al., 2010; Liu et al., 2010; MacKay et al., 2010;

Smogorzewska et al., 2010). These studies show that FAN1 interacts with
FANCD2 and that the depletion of FAN1 leads to ICL sensitivity. FAN1 is a
structure-specific nuclease, containing four characterized domains: ubiquitinbinding domain UBZ, DNA binding domain SAP (SAF-A/B, Acinus and PIAS),
protein-protein interaction domain TPR (tetratricopeptide repeat), and nuclease
domain VRR_nuc (virus-type replication-repair nuclease) (Figure 1.2) (Iyer et al.,
2006; Kinch et al., 2005). The UBZ domain of FAN1, which belongs to RAD18
family of zinc fingers proteins that are commonly found in DNA damage response
proteins, facilitates its binding to the monoubiquitinated ID2 complex (Hofmann,
2009; Kratz et al., 2010; Liu et al., 2010; MacKay et al., 2010; Smogorzewska et
al., 2010). The UBZ domain of FAN1 is not found in unicellular eukaryotes, but is
highly conserved in many multicellular organisms. Interestingly, the presence of
the UBZ domain is concurrent with the evolution of the majority of FA genes
including FANCD2 (MacKay et al., 2010; Patel and Joenje, 2007; Smogorzewska
et al., 2010). The VRR_nuc domain of FAN1 is well conserved from bacteria to
humans and contains a PD-D/E(X)K motif that is often found in the active site of
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many restriction endonucleases as well as MUS81 and XPF endonucleases
(Kinch et al., 2005; Kosinski et al., 2005).

FAN1 is necessary for the resistance to ICL-inducing agents such as
MMC, cisplatin and HN2 (nitrogen mustard derivative) in multiple model systems
from S. pombe to mammals (Airik et al., 2016; Fontebasso et al., 2013; Kratz et
al., 2010; Lachaud et al., 2016a; Liu et al., 2010; MacKay et al., 2010;
Smogorzewska et al., 2010; Thongthip et al., 2016; Yoshikiyo et al., 2010; Zhou
et al., 2012). Treatment of FAN1-deficient human cells with ICL-inducing agents
leads to proliferation defect and chromosomal aberration that are accompanied
by high level of DNA damage (Kratz et al., 2010; MacKay et al., 2010). To date,
FAN1 has not been convincingly shown to be required for the repair of other
types of DNA damage.

In addition to the ID2 complex, FAN1 also interacts with DNA mismatch
repair proteins. The analysis of MLH1 and PMS2 interactome revealed several
peptides of FAN1, while reciprocally, the top-scoring candidates from the
proteomic study of FAN1’s interacting partners included MLH1, MLH3, PMS1,
and PMS2 (Cannavo et al., 2007; Kratz et al., 2010; MacKay et al., 2010;
Smogorzewska et al., 2010). In a size exclusion study, FAN1 was found to form
two subcomplexes one with FANCD2 and FANCI and the other with MLH1
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(MacKay et al., 2010). It remains to be shown if FAN1 functions within the DNA
mismatch repair pathway.

1.5 FAN1 and ICL repair
Although there are several lines of evidence that indicate the importance
of FAN1 in the protection of cells and organisms from ICL-induced damage, its
role during ICL repair remains elusive. Given the direct association between
FAN1 and the monoubiquitinated ID2 complex, it has been proposed that FAN1
nuclease activity might function downstream of ID2 monoubiquitination. As such,
it could contribute to ICL incision, processing of the excised crosslink, or could
even function later during homology directed repair of DNA double-strand break
(DSB) intermediates or in the resolution of Holliday junctions (Smogorzewska et
al., 2010).

1.5.1 The structure and nuclease activity of FAN1
To date, several high-resolution structures of FAN1 have been analyzed
either alone or in complex with different DNA substrates (Gwon et al., 2014;
Wang et al., 2014; Zhao et al., 2014). These studies gave some insight to the
mechanism of DNA binding and catalysis by FAN1. The structure solved by the
Pavletich lab shows FAN1 as a monomeric protein with a bilobal structure
consisting of 223-residue N-terminal domain (NTD) and a 415-residue C-terminal
domain (CTD) containing a nuclease motif. The protein was crystalized with DNA
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substrate with a pre-nicked 1-nucleotide 5’ flap carrying 5’ phosphate group and
a post-nicked 4-nucleotide 3’ flap. The NTD binds to the pre-nicked duplex and 3’
flap, whereas the CTD binds to the 5’ flap and post-nicked duplex, distorting the
DNA substrate into a V-shape molecule. The authors proposed that this structure
would permit sequential 3-nucleotide stepwise incisions across the crosslink
(Wang et al., 2014). The structures solved by the Sung lab demonstrates the
dimerization of FAN1 monomers. The binding to 5’ flap DNA substrates promotes
a dimerization of FAN1 in a ‘head to tail’ conformation. The TPR and NUC
domains of one FAN1 molecule interact with the SAP domain of the other FAN1
molecule. Within the asymmetric FAN1 dimer, one of the monomers appears to
have a primary role in catalysis by engaging DNA in its active site whereas the
other monomer plays an ancillary role, facilitating substrate orientation and DNA
flap unwinding (Zhao et al., 2014). The authors propose that the dimerization of
FAN1 promotes the unwinding of the DNA duplex and guides the ssDNA towards
the active site for incision (Zhao et al., 2014). Unwinding of the DNA duplex
would be critical for facilitating the endonuclease activity of FAN1 on its ICL
substrate, as the 5’ flap incision is strongly inhibited when the crosslink is located
close to the flap branch point (Zhao et al., 2014).

FAN1 possesses both endonuclease and exonuclease activity on
crosslinked and non-crosslinked DNA substrates. FAN1 endonuclease activity
exhibits preference for nicked and 5’ flap DNA structures (Gwon et al., 2014;
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MacKay et al., 2010; Smogorzewska et al., 2010; Wang et al., 2014). Structural
analyses by different groups suggests that binding of FAN1 to the DNA substrate
is facilitated by the positively charged surface of the SAP domain, residues
flanking the SAP domain and the sugar-phosphate backbone of the DNA duplex
downstream of 5’ flap structure (Gwon et al., 2014; Wang et al., 2014; Zhao et al.,
2014). It is proposed that the direct interaction of the SAP domain with
crosslinked DNA provides proper structural remodeling of the DNA substrate,
which is required for incision by the nuclease domain of FAN1 (Gwon et al.,
2014; Wang et al., 2014; Zhao et al., 2014). Cleavage of 5’ flap DNA of the ICLstalled replication fork-like structures is followed by exonucleolytic processing of
nicks to digest across the crosslink in 3-nucleotides stepwise incisions. This
sequence of events is proposed to allow de facto ICL unhooking (Figure 1.2)
(Pizzolato et al., 2015; Zhao et al., 2014).
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Figure 1.2 FAN1 domain structure and model of FAN1 nuclease
activity.
(A) FAN1 contains 4 characterized domains including the UBZ, SAP, TPR,
and NUC (nuclease) domains. (B) FAN1 is thought to participate in the ICL
incision step. Potential substrates include the dual and single fork structures
as well as linear DNA with an ICL. In vitro, FAN1 exhibits preference for the
5’ flap structure via its endonuclease activity and the 5’-3’ exonuclease
activity allowing it to digest DNA across the ICL.
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1.5.2 Redundant functions of FAN1 and other structure-specific nucleases
in ICL repair
FAN1 is clearly necessary for resistance to ICL-inducing agents. However,
immunodepletion of FAN1 had no effect on the incision of a cisplatin ICL in the X.
laevis egg extract system (Douwel et al., 2014). Normal repair in this setting
might be attributed to the fact that FAN1 may act on structures other than dual
convergent forks that are required for repair of the damaged plasmids in this
system. Alternatively, FAN1 may be functionally redundant with other ICL repair
nucleases such as MUS81, SLX1 or SNM1A (reviewed in (Zhang and Walter,
2014). SLX1 and MUS81-EME1 are associated with SLX4 and are genetically
epistatic in ICL repair (Castor et al., 2013; Kim et al., 2013). SLX1 is a
promiscuous nuclease, which like FAN1 prefers 5’ flap DNA substrates in vitro.
Therefore, it is possible that SLX1 could potentially provide 5’ flap endonuclease
activity required for crosslink incision in the absence of FAN1 (Fricke and Brill,
2003).

Aside from FAN1, the SNM1 family of proteins are the only crosslink repair
nucleases that possess a 5’-3’ exonuclease activity (Hejna et al., 2007; Wang et
al., 2011). In yeast, Pso2 is the single SNM1 protein member, and is important
for ICL resistance (Zhang and Walter, 2014). In higher eukaryotes, three SNM1
homologs - SNM1A, SNM1B (Apollo) and SNM1C (Artemis) exist, with SNM1A
and SNM1B being implicated in ICL resistance. (Cattell et al., 2010; Ishiai et al.,
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2004). SNM1A is the ortholog which has the most similarity to Pso2, and is the
only one that can complement the ICL sensitivity of pso2Δ yeast (Hazrati et al.,
2008). SNM1A deficiency, nonetheless, confers mild crosslink sensitivity in
mouse and human cells (Ahkter et al., 2005; Dronkert et al., 2000; Wang et al.,
2011). This suggests that SNM1A plays a minor role in mammalian ICL repair or
that another ICL-repair nuclease, such as FAN1, compensates for the loss of
SNM1A. Consistent with possible redundant roles of SNM1A and FAN1, the S.
pombe Fan1 was recently shown to be non-epistatic with Pso2, as pso2Δfan1Δ
displays greater cisplatin sensitivity than a single pso2Δ or fan1Δ mutant alone
(Fontebasso et al., 2013).

1.5.3 The significance of the UBZ domain and the genetic interaction
between FAN1 and the FA pathway
The UBZ domain located at the N-terminus of FAN1 facilitates binding
between FAN1 and the monoubiquitinated lysine residues of FANCI/FANCD2
(Figure 1.2A). However, the significance and function of this interaction has
remained unclear. The UBZ-mediated interaction with the ID2 complex was first
shown to be necessary for localization of FAN1 to ICL-induced DNA damage foci
and psoralen-induced damage, arguing that the ICL repair activity of FAN1 may
depend on the UBZ domain (Kratz et al., 2010; Liu et al., 2010; MacKay et al.,
2010; Smogorzewska et al., 2010). In one of the studies, the UBZ domain was
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also shown to be necessary for resistance to DNA ICLs (Liu et al., 2010).

More recent data from our and Seidman lab show that FAN1 lacking the
UBZ domain can still be recruited to the site of damage (Thongthip et al., 2016).
In experiments testing the recruitment of FAN1 to psoralen-induced ICLs, the
Seidman lab has shown that the SAP domain was critical for rapid recruitment of
FAN1 to ICLs. The UBZ-dependent phase of ICL-recruitment occurred more
slowly and coincided with the localization of FANCD2 at ICLs.

These

observations may reflect the dependency of the UBZ-dependent recruitment or
retention of FAN1 at sites of damage on the monoubiquitination of
FANCI/FANCD2 (Thongthip et al., 2016; Yan et al., 2012). In our hands, this
increased recruitment/retention of FAN1 was not necessary for resistance to ICL
damage since expression of FAN1 with mutations in the UBZ domain fully
rescued ICL sensitivity of FAN1-deficient human cells (Zhou et al., 2012). We
concluded that SAP domain plays a more important role in the recruitment of
FAN1 to ICLs and that FAN1 can participate in ICL repair independently of the
UBZ domain.

Collectively, findings from multiple studies indicate that interaction
between FAN1 and the ID2 complex is not required for ICL repair activity of
FAN1 and that the crosslink repair function of FAN1 could occur independently of
the FA pathway. Evidence from studies in the chicken DT40 cell line also support
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this view as FAN1-/-FANCC-/- cells are more sensitive to cisplatin than wild-type,
FAN1-/-, or FANCC-/- single knockout cells (Yoshikiyo et al., 2010). Whether the
crosslink repair function of FAN1 is epistatic with the FA pathway in mammalian
cells, is therefore a question of significant importance and will be experimentally
addressed below.

1.6 Endogenous sources of DNA damage that underlie the pathogenesis of
ICL repair disorders
The ICL repair pathway most likely evolved to cope with the challenges
posed by endogenously produced ICL-inducing agents. Several sources of
endogenous ICLs that require FA pathway’s repair activity have been proposed.
These include the signaling molecule nitric oxide as well as the abundant abasic
sites (also known as AP or apurinic/apyrimidinic site), which can react with the
opposite strand of DNA to form ICLs (Dutta et al., 2007). However, reactive
aldehydes are the most well characterized sources of DNA damage that have
been shown to affect bone marrow and other organ system functions in vivo in an
FA pathway deficient setting (Garaycoechea et al., 2012; Langevin et al., 2011;
Oberbeck et al., 2014; Pontel et al., 2015).

Aldehydes are reactive small molecules that can be found both in the
environment and within cells as the by-products of metabolism. Examples include
the products of lipid peroxidation, trans-4-hydroxy-2-nonenal, malondialdehyde,
crotonaldehyde and acrolein, (Huang et al., 2010; Scharer, 2005; Stone et al.,
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2008), but also formaldehyde and acetaldehyde which can be formed from the
protein and nucleic acid demethylation and the metabolism of amino acids and
nucleotides (Jensen et al., 2015; Loenarz and Schofield, 2008; Matsuda et al.,
1999; Ogawa et al., 2000; Walport et al., 2012). Cells possess powerful
detoxification systems that limit the concentration of reactive aldehydes in
different organs. The majority of aldehyde detoxifying enzymes belong to the
aldehyde dehydrogenase gene (ALDH) superfamily which consists of 19 gene
members in humans (Jackson et al., 2011; Marchitti et al., 2008; Yoshida et al.,
1998). ALDH2 is one of the most characterized ALDH family members, as it is
involved in the conversion of acetaldehyde, an intermediate of ethanol
metabolism, to acetate (Goedde and Agarwal, 1990; Klyosov et al., 1996).
Besides

ALDHs,

the

glutathione-dependent

alcohol

dehydrogenase

5

(ADH5/GSNOR), a class III alcohol dehydrogenase (ADH) plays a key role in the
clearance of formaldehyde, a simpler but more toxic type of aldehyde (Sanghani
et al., 2000; Staab et al., 2009).

Recent work has implicated both acetaldehyde and formaldehyde as the
endogenous ICL-inducing agents that create a problem when Fanconi anemia
proteins are not functional. It has been shown that an increase in endogenous
acetaldehyde or formaldehyde level due to ALDH2 or ADH5 deficiency leads to
chromosomal instability and results in severe proliferation defects in FA-deficient
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cell lines (Langevin et al., 2011; Marietta et al., 2009; Mechilli et al., 2008;
Rosado et al., 2011; Wang et al., 2000).

1.6.1 Acetaldehyde-induced ICL damage
Acetaldehyde is a toxic agent found in tobacco smoke, vehicle exhaust
and some dietary products. Acetaldehyde is a common endogenous by-product
of threonine, tyrosine, b-alanine and deoxyribose phosphate metabolisms
(Jacobsen, 1950; Matsuda et al., 1999; Ogawa et al., 2000). Acetaldehyde can
also be produced by oxidation of ethanol by the NAD-dependent alcohol
dehydrogenases in the liver (Zakhari, 2006).

Acetaldehyde treatment induces H2AX phosphorylation, stimulates
mutagenesis, and increases sister chromatid exchanges in cultured mammalian
cells (Bird et al., 1982; Dellarco, 1988; Ristow and Obe, 1978; Wang et al., 2001).
Mouse and human cells deficient for the FA pathway display aberrant
chromosomes and hypersensitivity upon treatment with acetaldehyde (Langevin
et al., 2011; Marietta et al., 2009; Mechilli et al., 2008; Ridpath et al., 2007).

To study the effect of acetaldehyde detoxification on cells lacking the FA
pathway, the Patel lab has generated mice that lack both the FA pathway and
ALDH2. Fancd2-/-Aldh2-/- and Fanca-/- Aldh2-/- mice show aberrant embryonic
development as well as birth defects (Garaycoechea et al., 2012; Langevin et al.,
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2011; Oberbeck et al., 2014).

The double Fancd2-/-Aldh2-/- mutant animals

have a reduced survival rate, with some embryos dying between embryonic day
9.5 and 13.5. In order to produce viable pups, the pregnant females need to
maintain at least one wild-type Aldh2 allele (Langevin et al., 2011). The presence
of the maternal Aldh2 is even more significant for the development of Fanca-/Aldh2-/- embryos, as they can only be born if the embryos are surgically
transferred to a mother that is homozygous for wild-type Aldh2. Despite this
rescue strategy, Fanca-/-Aldh2-/- mice are born with developmental defects such
as eye and craniofacial abnormalities (Oberbeck et al., 2014). Additionally,
treatment with ethanol during pregnancy can promote the developmental
abnormalities in Fancd2-/-Aldh2-/- and Fanca-/-Aldh2-/- double-mutant pups
(Langevin et al., 2011).

Fancd2-/-Aldh2-/- mice that were derived from Aldh2+/- mothers, allowing
them to develop normally, succumb to acute lymphoblastic leukemia (ALL) by 6
months of age. Majority of the remaining survivors develop spontaneous bone
marrow failure due to hematopoietic stem cell attrition (Garaycoechea et al.,
2012; Langevin et al., 2011). The frequency and function of the hematopoietic
stem and progenitor cells in Fancd2-/-Aldh2-/- mice are drastically reduced
compared to wild-type or single mutant animals. Further analysis revealed that
Fancd2-/-Aldh2-/- HSCs are inherently damaged and demonstrate induction of gH2AX that is exacerbated following ethanol feeding (Garaycoechea et al., 2012).
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These studies indicate a requirement for acetaldehyde detoxification by ALDH2
for the normal development, hematopoietic stem cell function, and tumor
suppression, particularly in the absence of the FA pathway.

The relevance of acetaldehydes in the pathogenesis of Fanconi anemia
has also been validated in human studies. Concomitant ALDH2 deficiency
greatly exacerbates developmental abnormalities, bone marrow failure, and
leukemia development in Japanese FA patients (Hira et al., 2013). Strikingly, FA
patients with a single allele of the dominant negative ALDH2 variant (rs671)
display accelerated progression to bone marrow failure. Furthermore, some FA
patients with biallelic ALDH2 rs671 variant exhibit an onset of myelodysplastic
syndrome and bone marrow failure at an age as young as 4 months.

1.6.2 Formaldehyde-induced ICL damage
Like acetaldehyde, formaldehyde is found in the environment as a
breakdown product of compounds such as tobacco smoke, and the sweetener
aspartame. It is also formed endogenously as a byproduct of metabolic reactions
(Jensen et al., 2015; Trocho et al., 1998). Endogenous formaldehyde can be
derived

from

oxidative

demethylation

reactions,

for

instance

through

demethylation of histones, RNA, and DNA by KDM1/JMJC or ABH family of
enzymes within the nucleus (Loenarz and Schofield, 2008; Pontel et al., 2015;
Walport et al., 2012). Formaldehyde is highly mutagenic and genotoxic due to its
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ability to introduce DNA monoadducts (McGhee and von Hippel, 1977). DNAprotein crosslinks (DPCs) (Casanova-Schmitz and Heck, 1983; MaganaSchwencke and Ekert, 1978; Solomon and Varshavsky, 1985), and DNA
interstrand crosslinks (Auerbach, 1949; Herskowitz, 1950; Lu et al., 2010).

The FA pathway has been shown to be important for the repair of
formaldehyde-induced damage. FA pathway deficient DT40 chicken cells,
primary mammalian cells as well as cancer cell lines are hypersensitive to
formaldehyde (Pontel et al., 2015; Ridpath et al., 2007; Rosado et al., 2011). The
combined inactivation of Fancd2 and the formaldehyde detoxifying enzyme Adh5
in the chicken DT40 cells results in synthetic lethality (Rosado et al., 2011).

The Fancd2-/-Adh5-/- double mutant animals display HSC dysfunction,
which leads to bone marrow failure and leukemia (Pontel et al., 2015).
Additionally, Fancd2-/-Adh5-/- animals develop liver and kidney karyomegaly
which may be associated with their accelerated degeneration. The kidney failure
observed in Fancd2-/-Adh5-/- is primarily caused by glomerular damage, which
manifests as a significant change in the glomerular anatomical structure,
accompanied by severe proteinuria. Animals display an increase in the level of
karyomegaly (enlarged nuclei) in the renal tubular cells and liver hepatocytes.
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At this point it is unclear if other reactive aldehydes will have influence on
the phenotypes of Fanconi anemia pathway deficient human or mice.

It is

unknown if other repair pathways are involved in clearance of acetaldehyde- or
formaldehyde-induced DNA damage. This question will be explored in this thesis
for FAN1.

1.7 FAN1 is mutated in patients with Karyomegalic Interstitial Nephritis
(KIN)
FAN1 was considered a candidate FA gene based on the observation that
there is a direct association between FAN1 and the ID2 complex and the finding
that its nuclease activity is required for ICL resistance. Unexpectedly, biallelic
loss of function mutations in FAN1 were identified in patients with Karyomegalic
Interstitial Nephritis (KIN) (Zhou et al., 2012). KIN is a chronic kidney disease,
characterized by the presence of enlarged, polyploid (karyomegalic) and
hyperchromatic nuclei in the proximal and distal tubules of the kidney (Godin et
al., 1996; Mihatsch et al., 1979; Spoendlin et al., 1995). It is a rare disease with
less than 50 cases being reported so far (Isnard et al., 2016). Patients with KIN
develop progressive kidney disease, which eventually leads to early onset of
end-stage kidney failure in 20-30 year olds (Mihatsch et al., 1979; Spoendlin et
al., 1995; Zhou et al., 2012).
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The urine of KIN patients typically show glucosuria and mild proteinuria,
whereas hematuria is rare (Bhandari et al., 2002; Isnard et al., 2016; Mihatsch et
al., 1979). Histologically, the kidney of KIN individuals display tubular basement
membrane degeneration, tubular atrophy with significantly thicker tubular
basement membrane, microcysts, interstitial infiltrations and pronounced fibrosis
(Zhou et al., 2012). In addition to the renal tissue, systemic karyomegaly in other
tissues such as liver, lung, brain, skin, and digestive tissues has also been
observed in many patients (Burry, 1974; Mihatsch et al., 1979; Sclare, 1976).
Furthermore, a number of cases exhibit elevated serum markers of hepatocyte
damage, mild anemia and recurrent upper respiratory infections of unknown
etiology (Bhandari et al., 2002; Godin et al., 1996; Mihatsch et al., 1979;
Spoendlin et al., 1995).

Genetically, KIN is caused by autosomal recessive mutations in FAN1,
with mostly nonsense mutations that lead to open reading frame truncations
(Zhou et al., 2012). A number of missense mutations found in 3 of the studied
families, are in the conserved functional nuclease domain, suggesting that the
nuclease activity of FAN1 is important in protection against KIN development
(Zhou et al., 2012). It is unclear whether KIN is driven by endogenous or
exogenous

sources

of

lesions.

Viral

infections

and

exposure

to

immunosuppressants or environmental genotoxins such as ochratoxin A, heavy
metals or herbal medicines are typically excluded in cases described in the
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literature (Bhandari et al., 2002; Godin et al., 1996; Mihatsch et al., 1979; Radha
et al., 2014; Uz et al., 2011). Based on our current knowledge that FAN1 is
necessary for ICL repair, the likely damage that accumulates in KIN patients are
ICLs but their source is unknown.

In this thesis, I will present our studies on the ICL repair function of FAN1
and the pathogenesis of Karyomegalic Interstitial Nephritis (KIN) that develops as
a result of FAN1 deficiency. Using human KIN-patient and Fan1-deficient mouse
cell lines, we show that FAN1 is required for ICL resistance in both human and
mice. FAN1 possesses ICL repair activity that is independent of the FA pathway,
yet FAN1 is redundant with SNM1A, another ICL repair nuclease. I will also
describe Fan1-deficient mouse model that displays characteristics of KIN
including the presence of kidney and liver karyomegaly. The enlargement of
nuclei in Fan1-deficient kidney and liver occurs progressively with age and is a
result of genome endoreduplication. The hematopoietic stem and progenitor cells
of Fan1-deficient animals are susceptible to crosslink-inducing agent but not to
ionizing irradiation. Finally, we provide evidence that formaldehyde and
acetaldehyde are unlikely the endogenous sources of damage that drive the
pathogenesis of KIN.
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Chapter 2: ICL repair functions of FAN1 in
human and mice
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2.1 Introduction
The contribution of FAN1 to ICL resistance has been firmly established
(Kratz et al., 2010; Liu et al., 2010; MacKay et al., 2010; Smogorzewska et al.,
2010). It is now clear that mutations in FAN1 lead to kidney disease in humans
(Zhou et al., 2012), a disease that is distinct from Fanconi anemia. This chapter
describes experiments that take advantage of cell lines from KIN patients and a
mouse model of the human disease, to answer questions that remain about the
function of FAN1. It explores the significance of FAN1 interaction with the
FANCD2 for ICL repair, the genetic interaction of FAN1 with other nucleases
implicated in ICL repair, and the organismal consequences of FAN1 dysfunction
with and without exogenous DNA damage.

Results
2.2 Characterization of FAN1’s functions using human KIN patient cells and
human tissues
2.2.1 FAN1 deficiency causes cellular sensitivity to DNA crosslink-inducing
agents in KIN patient cells
Depletion of FAN1 using siRNA and shRNA has revealed that FAN1 was
necessary for cellular resistance to ICLs (Kratz et al., 2010; Liu et al., 2010;
MacKay et al., 2010; Smogorzewska et al., 2010).

To confirm that FAN1

deficiency identified in the germline of patients with KIN also leads to sensitivity
to ICL-inducing agents, patient fibroblasts were tested for sensitivity to MMC.
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Patient cell line (A1170) carrying homozygous FAN1 truncation leading to lack of
FAN1 protein, exhibited a survival defect and a significant induction of
micronuclei, a hallmark of chromosomal instability when treated with MMC
(Figure 2.1A, B). Importantly, the ICL sensitivity of the patient cells was rescued
when wild-type copy of FAN1 was introduced into the cells (Figure 2.1A). This
result was consistent with the proposed role of FAN1 in genome maintenance
and the repair of ICLs. It is worth noting that KIN patient cells were significantly
less sensitive to MMC then the Fanconi anemia (FA) patient cells lacking FANCA
(RA3087) (Figure 2.1A).

2.2.2 Differential expression of FAN1 and FANCD2
The distinct phenotypes of KIN and FA could stem from the differential
expression of FAN1 and FA proteins in a tissue specific manner. FAN1 could
potentially be highly expressed in the kidney whereas FA proteins might be more
enriched in the bone marrow, the tissues that are affected in the corresponding
disorders. The study of FAN1 and FANCD2 gene expression revealed that FAN1
transcripts could be detected in all tissues, although at different levels of
expression (Zhou et al., 2012). FAN1 mRNA was expressed at a higher level
than FANCD2 in parenchymatous organs, including the kidney, liver and
neuronal tissues, whereas FANCD2 expression exceeded FAN1 in lymphatic or
bone marrow-derived tissues as well as in skin and testis (Zhou et al., 2012). The
fact that FAN1 was expressed at a particularly high level in the parenchymatous
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organs, raises the possibility that those tissues might depend on FAN1 for its
normal function. To corroborate the findings from FAN1 gene expression study,
we examined FAN1 expression at the protein level across multiple tissues
including the kidney and liver that are affected in KIN. While full-length FAN1
protein was expressed at a particularly high level in the kidney tissue, a
significantly lower level was detected in the liver and the bone marrow (Figure
2.1C, D). However, as will be discussed later, MMC treatment resulted in bone
marrow failure in Fan1-deficient mice. This observation could be explained if
FAN1 is expressed in a subset of bone marrow cells (potentially the stem and
progenitor cells), to protect against ICL-induced bone marrow failure.

2.2.3 FANCD2 Ubiquitination, G1/S and G2/M checkpoints are intact in
human FAN1-deficient cells
To assess if DNA damage signaling and the activation of FA pathway are
compromised in FAN1-deficient cells, we first tested if FAN1 was required for the
monoubiquitination of FANCD2 and FANCI in FAN1 patient fibroblasts (A1170)
and lymphocytes (A4466, A4486, A4385) (Zhou et al., 2012). The loss of function
mutations of FAN1 did not affect the presence of FANCD2 and FANCI
monoubiquitination, suggesting that the FA pathway is activated even in the
absence of FAN1 (Figure 2.2A, B)(Zhou et al., 2012).
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We next examined whether FAN1 was involved in the regulation of G1/S
and G2/M checkpoints following DNA damage treatments. To monitor the G1/S
checkpoint, we analyzed the level of early S-phase cells after the treatment with
ionizing radiation (IR) by measuring the BrdU+ cells with DNA content close to 2N.
Cells null for ATM, kinase necessary for DNA damage signaling abated the G1/S
checkpoint, allowing the progression of the IR-damaged cells into S-phase. In
contrast, the absence of FAN1 or FA protein did not affect the G1/S checkpoint,
as cells were effectively blocked in G1 following the IR treatment (Figure 2.2C, D).
Similarly, the G2/M checkpoint appeared to be intact in cells lacking FAN1 or
FANCA. FAN1- and FANCA-deficient cells were impeded from entering mitosis
to the same extent as BJ wild-type cells following IR, unlike the G2/M checkpoint
deficient ATR-depleted cells (Figure 2.2E, F).
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Figure 2.1 FAN1 deficiency causes ICL sensitivity in KIN patient cells
and FAN1 is highly expressed in the kidney tissue.
(A) Survival of wild-type fibroblasts (BJ), RA3087 FANCA-/-, A1170 FAN1-/, and A1170 cells transduced with eV (empty vector), or WT (wild-type)
FAN1. Cells were treated with MMC. After 6 days, cell numbers were
determined and normalized to the untreated control to calculate the
percentage of survival. Error bars indicate SD. (B) Blinded quantification of
cells with micronuclei following 1 hour of 1 µM MMC treatment. (C-D) FAN1
expression in human tissues. Lysates from indicated tissues were run and
immunoblotted with an antibody against FAN1 (RC394) (Left). Loading was
assessed by a staining with Ponceau dye (Right).
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Figure 2.2 FANCD2/FANCI ubiquitination and G1/S and G2/M
checkpoints are not affected in FAN1-deficient KIN patient cells.
(A-B) Monoubiquitination status of FANCD2 in patient cell lines. Indicated
cells were treated with 1 µM MMC for 24 hours and collected for western
blotting with anti-FANCD2 and anti-alpha tubulin antibodies. L indicates
long, monoubiquitinated form of FANCD2 and S is a short, non-modified
form. (C) Representative FACS profiles of G1/S checkpoint analysis. Cells
were analyzed by BrdU and PI (propidium iodide) before and after IR. (D)
Quantification of early S-phase cells with BrdU+ and DNA content around
2N. The number of early S-phase cells following IR-treatment was
normalized to the untreated control to calculate the % of G1/S transition
inhibition. (E) Representative FACS profiles of G2/M checkpoint analysis.
Cells were analyzed by phosphorylated H3 and PI (propidium iodide) before
and after IR. (F) Quantification of mitotic cells that were positive for
phosphorylated H3 with DNA content close to 4N. The number of mitotic
cells following IR-treatment was normalized to the untreated control to
calculate the % of G2/M transition inhibition.
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2.2.4 FAN1 has ICL repair activity that is non-epistatic with FA factors in
human cells
It was previously shown that deletion of FAN1 further sensitizes FANCCand FANCJ- deficient DT40 chicken cells to ICL-inducing agents. This indicates
that FAN1 has FA pathway-independent function in ICL repair (Yoshikiyo et al.,
2010). To examine whether this aspect of FAN1 function is conserved in human
cells, we tested whether depletion of the Fanconi anemia factors including
FANCD2, SLX4 or the SLX4-associated nucleases XPF and MUS81 in the
FAN1-mutant cells led to increase in ICL sensitivity. FAN1-positive BJ cells were
used as a control in the experiment.

Depletion of FANCD2, SLX4, XPF, or

MUS81 in FAN1-deficient cells caused greater MMC sensitivity than the level
observed in the corresponding FA factor-depleted BJ controls or in the nondepleted FAN1-/- cells (Figure 2.3A-E). These results suggested that, also in
human cells, FAN1 could function independently of the Fanconi anemia pathway
in ICL damage response.
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Figure 2.3 FAN1 has ICL repair function that is non-epistatic with the
FA pathway.
MMC sensitivity in A1170 FAN1-/- fibroblasts transfected with the siRNA
against genes previously implicated in crosslink repair (A) FANCD2
depletion, (B) SLX4 depletion, (C) MUS81 depletion, (D) XPF depletion, (E)
Immunoblot of expression levels of indicated proteins after siRNA-mediated
depletion in the A1170 cells used in the experiment shown in panel A-D.
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2.3 Characterization of Fan1 knockout mouse
2.3.1 Verification of Fan1 knockout in the mouse model
To investigate the cellular and organismal functions of FAN1, we
generated Fan1-deficient mice. The Fan1 locus was targeted in embryonic stem
cells using a conditional Fan1tm1a (KOMP)Wtsi (Fan1stop) construct (Knockout
Mouse Project [KOMP]) (Figure 2.4A). The correctly targeted clones were used
to create a mouse with a single Fan1stop allele, which was verified by Southern
blotting using probes at 5’ and 3’ of the targeted site. (Figure 2.4B, C).
Fan1+/stop males were crossed with FLPe deleter female mice to generate mice
carrying Fan1lox allele (Figure 2.4A). Mice carrying the disrupted Fan1 allele Fan1Δex3&4, which for ease of labeling, we refer to here as Fan1−, was
generated from the cross between Fan1+/lox male and E2a-Cre female mice.

Southern blotting using the probe located 5’ of the targeted locus and PCR
genotyping were performed to verify the generation of Fan1-/- mice (Figure 2.5AD). Deletion of exons 3 and 4 from Fan1 gene resulted in low level of Fan1
expression with Fan1 transcript reduced to about 50% of the wild-type level in the
Fan1+/- heterozygotes and lower than 10% in Fan1-/- animals. At the protein
level, no protein expression could be detected in mouse embryonic fibroblasts
(MEFs) obtained from homozygous Fan1-/- embryonic day 13.5 (E13.5) embryos
(Figure 2.5E-G). Together these results suggest that Fan1 expression is
abrogated in the Fan1 knockout mouse that we engineered.
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To assess whether FAN1 deficiency recapitulates the phenotypes
observed in human cells lacking FAN1, we examined the cellular sensitivity of
Fan1-/- cells to ICL-inducing agent MMC when compared with Fan1+/+ or
Fan1+/- MEFs. Similar to human cells, Fan1-/- MEFs displayed significant growth
defects and an increase in the level of chromosome breaks and radial
chromosomes when cells were treated with MMC (Figure 2.6A-C). Importantly,
the cellular sensitivity and the increased breakage in Fan1-/- MEFs after MMC
treatment could be fully rescued when cells were transduced with wild-type
mouse Fan1 cDNA (Figure 2.6D, E, Figure 2.8C). These experiments show that
the crosslink repair defect in Fan1-/- MEFs is due to a lack of functional FAN1
protein.

Fan1-deficient MEFs were also more sensitive to treatment with
acetaldehyde and formaldehyde, both of which have been implicated as
endogenous sources of DNA ICLs (Figure 2.6F, G). However, the level of
sensitivity to all tested ICL-inducing agents was significantly lower than that of
MEFs deficient in SLX4 (Slx4f3/f3), a scaffold protein for three nucleases,
including XPF, which is the major effector of the FA pathway (Figure 2.6A, F, G).
Consistent

with

previous

reports,

Fan1-deficient

MEFs

did

not

show

hypersensitivity to either camptothecin (CPT) or hydroxyurea (HU), suggesting
that FAN1 is specifically required for the repair of DNA ICLs and no other S-
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phase-associated replication blocks (Figure 2.6H, I; (Kratz et al., 2010; Liu et al.,
2010; MacKay et al., 2010; Smogorzewska et al., 2010).
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Figure 2.4 Targeting strategy to create the Fan1-deficient mouse.
(A) Targeting strategy for Fan1-deficient mouse. Coding exons 1-6 of the
Fan1 genomic locus in wild type (chromosome 7), the Fan1stop, the
Fan1lox and the Fan1Δex3&4 mutant alleles generated are shown. The
wild-type Fan1 gene contains a 20.5 kb BamHI restriction fragment that
hybridizes to the 5’(red) and 3’(dark green) probes. A correctly targeted
Fan1stop locus contains a 13.8 kb fragment that hybridizes to the 5’ probe
and 7.5 kb fragment that hybridizes to the 3’ probe. The neomycin cassette
(pink), the FRT (blue), the LoxP (green), the splice acceptor (SA), and the
poly A (pA) sites are also shown. The cross between Fan1+/stop and FLP
deleter mice generated Fan1+/lox. The cross between Fan1+/lox and
FVB/N-Tg(Ella-cre)C5379Lmgd/J mice to derive Fan1+/-(Δex3&4) are
shown. The comparison between full-length wild type FAN1 transcript and
Fan1-(Δex3&4) transcript lacking exon 3 and exon 4 are shown. Red
asterisk (*), stop codon. The comparison between full-length wild type FAN1
protein with the domain architecture and the expected truncated FAN1
protein product expressed from Fan1Δex3&4 allele are shown. (B, C) 5’ and
3’ Southern blot analyses of BamHI–digested genomic DNA from Fan1+/+
and Fan1+/stop mice. CR, cross-reacting band.
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Figure 2.5 Verification of Fan1 knockout mouse.
(A) Schematic of the wild-type and Fan1Δex3&4 mutant alleles. The wildtype Fan1 gene contains a 20.5-kb BamHI restriction fragment that can be
detected with a 5′probe (red line). A correctly targeted Fan1 locus harbors
a 3.1-kb deletion, including exons 3 and 4, resulting in a 17.4-kb fragment
that hybridizes to the same probe. The FRT and LoxP sites are indicated as
blue and green triangles, respectively. (B) Southern blot analysis of BamHIdigested gDNA from Fan1+/+, Fan1+/-, and Fan1-/- MEFs. (WT) Wild type;
(Mut) mutant. (C-D) Schematic showing primer positions used for
genotyping (top). Genotyping PCR for Fan1+ and Fan1- alleles using DNA
from MEFs of the indicated genotypes (bottom). (E) Schematic of exons 911 of Fan1, showing exon 10 q-PCR primers used in panel (F). (F)
Quantification of Fan1 mRNA level in MEFs of indicated genotypes. (G)
Immunoblot of extracts from MEFs of the indicated genotypes using an
antibody recognizing mouse FAN1. HAmFAN1 is N-terminally HA-tagged
mouse FAN1 and is expressed in Fan1-/- MEFs.
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Figure 2.6 FAN1 is necessary for resistance to DNA ICL damage in
MEFs.
(A) Survival of MEFs after treatment with the indicated doses of mitomycin
C (MMC). MEFs were treated in triplicate with increasing concentrations of
MMC. After 6 days, cell numbers were determined and normalized to untreated control to calculate the percentage of survival. Error bars indicate
SD. (B) Examples of metaphase spreads of Fan1+/+ (left) and Fan1-/(right) after exposure to 50 nM MMC for 24 h. Arrowheads indicate radial
chromosomes shown in the inset. (C) Quantification of chromosome
breakage of Fan1+/+ and Fan1-/- MEFs shown in B. (∗∗∗∗) P < 0.0001,
calculated using a t- test. (D) Complementation of MMC sensitivity in Fan1/- MEFs. Fan1-/- MEFs stably transduced with empty vector (eV) or vector
expressing HA-tagged mouse FAN1 (HA-mFAN1) were exposed to different
levels of MMC, as in A. Error bars indicate SD. (E) Immunoblot showing the
expression of HA-mFAN1 used in D. (F-G) Sensitivity to aldehydes of the
indicated

MEFs. MEFs

were

treated

in

triplicate

with

increasing

concentrations of acetaldehyde (0–8 mM) (F) or formaldehyde (0–300 μM)
(G) for 2 h before being washed three times with PBS and were cultured for
an additional 6 days in non-drug-containing medium. After 6 days, cell
numbers were determined and normalized to untreated control to calculate
the percentage of survival. Error bars indicate SD. (H) Survival of Fan1+/+
and Fan1-/- MEFs treated with hydroxyurea (HU). MEFs were treated in
triplicate with increasing concentrations of HU. Error bars, s.d.. (I) Survival
of indicated MEFs after camptothecin (CPT) treatment (0-20 nM). MEFs
were treated in triplicate with increasing concentrations of CPT. Error bars,
s.d..
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2.3.2 FAN1 participates in ICL repair independently of the UBZ domain
Our earlier work revealed that the UBZ domain was not important for the
ability of FAN1 to confer resistance to crosslinking agents in human cells (Zhou
et al., 2012). In that study, the UBZ mutated Cys44AlaCys47Ala human FAN1
fully rescued the ICL repair defect in the KIN patient cells. To assess which
domains of mouse FAN1 are important for ICL resistance, we expressed mouse
FAN1 with mutated UBZ (p.Cys44Ala;Cys47Ala), SAP (p.Leu480Pro), or
nuclease (p.Asp963Ala) domains in Fan1-/- MEFs and tested complementation
of ICL sensitivity in a survival assay. Unlike expression of wild-type mouse Fan1
cDNA, which was able to fully complement the MMC sensitivity of Fan1-deficient
MEFs, expression of cDNA carrying a mutation in the SAP or nuclease domain
resulted in no rescue (Figure 2.7A-C, E, F). In agreement with our previous study,
the UBZ-mutated Fan1 variant (p.Cys44Ala; Cys47Ala) behaved like the wildtype allele in this assay, indicating that FAN1-conferred ICL resistance is indeed
independent of its FANCD2/FANCI interaction in mammalian cells (Figure 2.7AD). This result was perplexing at the time, since the UBZ domain is critical for
stable localization of FAN1 to the sites of DNA damage (Smogorzewska et al.,
2010) and implies that a different domain of FAN1 might be important for
localization of FAN1 to the ICLs.
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Figure 2.7 The UBZ domain is dispensable for FAN1’s function in ICL
repair.
(A) Schematic representation of the mouse FAN1 protein indicating the
mutations in the key functional domains: C44A/C47A in the UBZ domain;
p.L480P in the SAF-A/B, Acinus, and PIAS (SAP) domain; and p.D963A in
(VRR- NUC) virus-type replication repair nuclease (NUC) domain. (B) MEFs
stably transduced with empty vector or vector expressing Fan1 variants with
mutations shown in A were MMC-treated. Error bars indicate SD. (C)
Immunoblot showing expression of mouse Fan1 mutant cDNAs in MEFs
used in B. (D) Quantification of chromosome breakage analysis of the
indicated MEFs treated with 50 nM MMC for 24 hours. (E) MEFs stably
transduced with vector expressing WT FAN1 or FAN1 D963A variant were
exposed to MMC (0-100 nM). Error bars, s.d. (F) Immunoblot showing
expression of WT FAN1 or FAN1 D963A in MEFs used in (E).
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2.3.3 FAN1 can function independently of the FA pathway
Having established that FAN1 can repair ICL damage independently of its
binding to FANCI/D2, we sought to determine whether FAN1 is epistatic with the
FA pathway. To elucidate this genetic interaction, we generated Fan1-/-Fancd2-/and Fan1-/-Fanca-/- double-knockout MEFs by crossing Fan1+/- mice with
Fancd2+/- (Houghtaling et al., 2003) or Fanca+/- (INoll et al., 2002) mice. Fan1-/Fancd2-/- animals generated from the intercrosses between Fan1-/-Fancd2+/mice were born at an observed ratio of 0.21, which is not significantly different
from the expected ratio of 0.25. Fancd2-/- and Fanca-/- MEFs were more
sensitive to MMC than the Fan1-/- cells (Figure 2.8A, B), confirming that the FA
pathway deficiency results in more pronounced inability to repair the MMCinduced damage. No further MMC-induced proliferation defect was apparent in
the double-mutant MEF cell lines compared with cells lacking Fancd2 or Fanca
alone (Figure 2.8A, 2.9A). This might be due to difficulty in measuring small
differences in cellular growth when cells are already very sensitive to DNA
damage as is the case of FA protein deficient cells. However, a deficiency in
Fan1 enhanced the degree of MMC-induced chromosomal abnormalities in
Fancd2-/- MEFs (Figure 2.8C). FAN1 therefore has a FANCD2-independent
function in the protection of cells from accruing ICL-induced chromosomal
instability. To assess the epistasis in human cells, we knocked out FAN1 in
FANCA or FANCD2 patient cell lines (Kim et al., 2013) using CRISPR/Cas9.
FAN1 deficiency further sensitized FANCA-/- cells to MMC, which could be

52

complemented back to levels of MMC resistance seen in FANCA-/- cells by
exogenously expressing wild-type FAN1 (Figure 2.9A-E, H). However, human
FAN1-/-FANCD2-/- cells did not exhibit significantly greater sensitivity to MMC
than FANCD2 single mutant cells (Figure 2.9F-H). Collectively, the analysis of
the UBZ domain mutant and the epistasis analysis supports the conclusion that
FAN1 has some function in ICL resistance that is independent of the FA pathway.
This FAN1-specific repair function is more subtle compared with the activity of
the FA-dependent pathway in mammalian cells, at least when MMC is used to
introduce ICLs.
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Figure 2.8 Fan1 and FA genes are non-epistatic in MEFs in
chromosome breakage assay.
(A) Survival of single Fan1-/- and Fancd2-/- and double Fan1-/-Fancd2-/MEFs following single treatment with MMC. After 6 days, cell numbers were
determined and normalized to the untreated control to calculate the
percentage of survival. (WT) Wild type. Error bars indicate SD. (B) Survival
of single Fan1-/-, Fanca-/-, and double Fan1-/-Fanca-/- deficient MEFs
following single treatment with MMC as described in A. Error bars indicate
SD. (C) Quantification of chromosome breakage analysis of the indicated
MEFs collected 24 h after 100 nM MMC treatment or left untreated. (∗∗) P <
0.01; (∗∗∗) P < 0.001, calculated by one- way ANOVA.
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Figure 2.9 Fan1 and FA genes are non-epistatic in human cells.
(A) Survival of wild-type fibroblasts (BJ) and A1170-22 FAN1-/-, RA3087
FANCA-/-, and two clones (1 and 2) of RA3087 FANCA-/-FAN1-/- cells
obtained by CRISPR/Cas9 gene editing. Cells were treated with MMC. After
6 days, cell numbers were determined and normalized to the untreated
control to calculate the percentage of survival. Error bars indicate SD. (B)
Immunoblot assessing expression of human FAN1 in human fibroblasts
used in A. (C) Immunoblot assessing expression of human FAN1
transduced in RA3087 FANCA-/-FAN1-/- clone 1 and clone 2. The clones
highlighted in red were used for the experiment outlined in (D, E). (D, E)
Survival of RA3087 FANCA-/-FAN1-/- clone 1 and clone 2 complemented
with HA-hFAN1. Cells were treated with MMC as described in A. MEFs
collected 24 h after 100 nM MMC treatment or left untreated. (∗∗) P < 0.01;
(∗∗∗) P < 0.001, calculated by one-way ANOVA. (F) Survival of wild-type
fibroblasts (BJ) and A1170-22 FAN1-/-, RA2645 FANCD2-/-, and four
clones (1, 5, 9 and 10) of RA2645 FANCD2-/-FAN1-/- cells obtained by
CRISPR/Cas9 gene editing. Cells were treated with MMC. After 6 days, cell
numbers were determined and normalized to the untreated control to
calculate the percentage of survival. Error bars indicate SD. (G) Immunoblot
assessing expression of human FAN1 in human fibroblasts used in F. (H)
Sequences of the targeted clones RA3087 FANCA-/-FAN1-/- clone 2,
RA2645 FANCD2-/-FAN1-/- clone 5, 9, and 10 used in A-G. The targeted
region of RA3087 FANCA-/-FAN1-/- clone 1 and RA2645 FANCD2-/-FAN1/- clone 1 could not be sequenced.
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2.3.4 Genetic interactions of Fan1 with Slx4 and Slx4-associated nuclease
Mus81
To determine the genetic interaction between Slx4, Slx4-associated
nuclease Mus81, and Fan1, we generated Fan1-/-Slx4f3/f3 and Fan1-/-Mus81-/MEFs through appropriate crosses. As shown earlier, Slx4f3/f3 cells were
significantly more sensitive to ICL-inducing agent compared to Fan1-/- cells
(Figure 2.6A, 2.10A). Inactivating Fan1 in Slx4f3/f3 cells did not have additive
effect on cellular sensitivity to MMC, suggesting that Slx4 plays a more dominant
role in ICL repair and is epistatic with Fan1 in mouse cells (Figure 2.10A).

Mus81-deficient MEFs were also significantly more sensitive to MMC than
wild-type cells but less sensitive then Fan1-/- cells (Figure 2.10B). Notably, lack
of MUS81 did not induce a remarkable increase in MMC-induced chromosomal
breakage, unlike that seen in Fan1 deficiency (Figure 2.10C). The doubleknockout Fan1-/-Mus81-/- MEFs generated through mouse intercrosses were as
sensitive to MMC as Fan1-/- cells, suggesting that Fan1 and Mus81 are epistatic.
Furthermore, Mus81 knockout also did not significantly change the extent of
chromosomal aberrations in MEFs lacking Fan1 (Figure 2.10C), although there
was a trend of increased abnormalities in the double-deficient cells.
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Figure 2.10 Genetic interactions of Fan1 with Slx4 and Mus81.
(A) Survival of Fan1-deficient, Slx4-deficient, and double-deficient MEFs
treated with the indicated levels of MMC. After 6 days, cell numbers were
determined and normalized to the untreated control to calculate the
percentage of survival. (WT) Wild type. Error bars indicate SD. (B) Survival
of Fan1-deficient, Mus81-deficient, and double-deficient MEFs treated with
MMC as described in (A) (WT) Wild type. Error bars indicate SD.

(C)

Quantification of chromosome breakage analysis of the indicated MEFs
treated with 50 nM MMC for 24 h. (∗∗∗∗) P < 0.0001; (n.s.) Not significant,
as determined by one-way ANOVA.
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2.3.5 FAN1 is functionally redundant with SNM1A
Recent biochemical analyses revealed that in vitro FAN1 could incise
close to a crosslink embedded in a variety of DNA substrates. In some cases, the
processing of crosslink substrates by FAN1 occurred at both the 5′ and 3′ sides
of the crosslink, leading to complete unhooking of the DNA crosslink (Pizzolato et
al., 2015; Wang et al., 2014). To date, SNM1A, a homolog of yeast Pso2, is the
only other known ICL-processing nuclease that is capable of digesting across an
ICL, leading to the possibility that FAN1 may be functionally redundant with
SNM1A in DNA ICL repair (Wang et al., 2011). To test this hypothesis, we used
three different shRNAs to deplete Snm1a in both wild-type and Fan1-/- MEFs. As
previously reported, Snm1a depletion alone did not cause significant sensitivity to
MMC in mouse cells (Figure 2.11A, B). However, depletion of Snm1a further
sensitized Fan1-deficient cells to MMC and the level of MMC sensitization
correlated with the level of Snm1a mRNA knockdown (Figure 2.11A-C). To
confirm these results in a cell line that completely lacks both FAN1 and SNM1A,
we knocked out Snm1a using CRISPR/Cas9. The double-deficient cells were
more sensitive to MMC than Fan1-/- cells and almost as sensitive as the SLX4deficient cells (Figure 2.11D, E). FAN1 with an inactivated UBZ domain was able
to complement an ICL repair defect in Fan1-/-shSnm1a MEFs to the level of wildtype cells, indicating that the UBZ domain is also dispensable for ICL resistance
in this setting. (Figure 2.11F, G).
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Figure 2.11 FAN1 and SNM1A are redundant in conferring resistance
to ICL-inducing agents.
(A) Survival of Fan1+/+ or Fan1-/- stably transduced with control shRNA or
shRNA targeting the Snm1a gene after treatment with MMC. Slx4f3/f3 was
used as a control. Error bars indicate SD. (B) Quantitative RT–PCR to
assess the level of Snm1a transcript depletion in cell lines used in B. (C)
Blinded quantification of cells with more than 20 γH2AX foci following MMC
treatment. (D) Survival of wild-type, Fan1-/-, Fan1-/-sgSnm1a.6, and
Slx4f3/f3 MEFs after MMC. Error bars indicate SD. Fan1-/- sgSnm1a.6 is a
clonal cell line with a biallelic frameshift mutation in Snm1a generated by
CRISPR/Cas9 genome editing. (E) Sequencing of the Fan1-/-sgSnm1a.6
MEF clone used in E. (F) Survival of the indicated MEFs after MMC
treatment. Fan1-/- MEFs depleted of Snm1a were stably transduced with
wild-type GFP-FAN1 or GFP-FAN1 C44A/C47A. Error bars indicate SD. (G)
Immunoblot showing the expression of wild-type GFP-FAN1 or GFP-FAN1
C44A/C47A in Fan1-/-shSnm1a.3 MEFs used in F.
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2.3.6 Lack of Fan1 results in progressive kidney and liver karyomegaly and
liver dysfunction
In order to assess if Fan1-/- mice are a good model for human KIN, we
analyzed the phenotypes of these mice. Fan1-/- mice were born at the expected
Mendelian ratio with no overt developmental abnormalities (Figure 2.12A). The
growth of Fan1-/- mice from birth until 12 weeks of age was comparable with
wild-type and heterozygous littermates (Figure 2.12B). Furthermore, Fan1-/- mice
were fertile, producing on average eight pups per cross, a number comparable
with those produced in crosses of heterozygous mice (Figure 2.12C).

Since one of the most pronounced characteristics of human KIN is the
presence of karyomegalic nuclei in cells of multiple tissues, we monitored the
histology of kidney and liver tissues in an aging cohort of mice. At 3 months, we
did not observe any remarkable differences in the distribution of nuclear areas
(cross-sectional area of nucleus) in renal tubular cells between Fan1-/- and wildtype animals (Figure 2.13A, B). Increased nuclear area became detectable in
Fan1 mice at 6 months of age (Figure 2.13B). The level of renal karyomegaly
further intensified with age, as the proportion of cells with larger than median
nuclear area rose more than twofold to ∼29% in 12-month-old Fan1 mice (Figure
2.13B, C). Notably, the number of tubular cells with nuclei larger than the median
area also went up to ∼10% in 12-month-old wild-type animals. However, the
nuclear area in this cohort did not exceed 1.2 times the median, unlike Fan1-/-
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animals at an equivalent age, which displayed a significant fraction (17%) that
were >1.2 of the median. Significant karyomegaly was absent from glomeruli of
Fan1-/- mice (Figure 2.13D)

Despite the presence of karyomegaly, we detected no significant elevation
in the level of blood urea nitrogen, creatinine, phosphorus, and magnesium in
Fan1-/- mice throughout the experiment (Figure 2.14A-D). These results indicate
that, even with apparent karyomegaly, the kidneys of the 18-month-old Fan1-/animals still retain sufficient function to support homeostasis. Additional
experimental manipulations to induce kidney injury may be necessary to elicit
overt kidney failure in this model.

Similar to the kidney, there was no discernible difference in the distribution
of the hepatocyte nuclear area between 3-month-old wild-type and Fan1-/- mice.
However, in 18-month-old mice without functional FAN1, a large fraction (>50%)
of nuclei became significantly enlarged (Figure 2.13E, F). In order to determine
whether the liver morphology had an impact on liver function, we analyzed liver
enzymes and serum proteins in 3- to 18-month-old animals. Fan1-/- animals
displayed elevated alanine transaminase and aspartate transaminase while
exhibiting lowered albumin and globulin levels (Figure 2.14E-H). The rise in
serum liver enzyme and concurrent reduction in serum proteins synthesized
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within the liver tissue indicate that the increase in karyomegalic hepatocytes
coincides with the deterioration of liver function.

Consistent with the polyploidization of the cells in KIN patients, the
enlarged cells in the kidney and liver tissue had increased numbers of
hybridization signals of fluorescence in situ hybridization (FISH) probes
recognizing three different chromosomes. In contrast, the spleen, which did not
display karyomegaly, had very few cells with more than two signals (Figure
2.15A-E).

Taken together, these results strongly support that FAN1 is required to
suppress age-dependent development of karyomegaly in the kidney and liver.
The Fan1-/- mouse model thus phenocopies the KIN conditions observed in
humans and will be instrumental in understanding human disease and potentially
the aging-associated changes in these tissues.
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Figure 2.12 Fan1-deficient mice are born at Mendelian ratio, grow
normally and are fertile.
(A) Fan1-/- mice are born at the expected Mendelian ratio. Viability of Fan1/- mice was determined by genotyping the progeny from crosses of Fan1+/female and Fan1+/- male at 21 days of age. p-value was calculated using
the χ2 -test. (B) Weight of male and female Fan1+/+, Fan1+/-, and Fan1-/mice from 3-12 weeks of age. (C) Fan1-deficient mice are fertile as
assessed by the comparison of litter size from Fan1+/- x Fan1+/- and
Fan1-/-x Fan1-/- crosses.
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Figure 2.13 Fan1 mice develop karyomegaly.
(A) Hematoxylin and eosin (H&E) staining of kidneys from Fan1+/+ and
Fan1-/- mice at 3 and 18 months. (B) Quantification of the nuclear area
(cross-sectional area) of tubular epithelial cells in the cortex of kidneys from
Fan1+/+ and Fan1-/- mice at 3, 6, 12, and 18 months. The area of each
nucleus was normalized to the median nuclear area present in the section
to control for fixation and embed- ding conditions. Data were then plotted
and grouped according to area. n = 3. Error bars indicate SD. (C)
Percentage of karyomegalic nuclei larger than the median nuclear area in
Fan1+/+ and Fan1-/- mice at 3, 6, 12, and 18 months. (∗) P < 0.05; (∗∗) P <
0.01, calculated by one-way ANOVA. n = 3. Error bars indicate SD. (D)
Quantification of the nuclear area of glomerular cells in Fan1+/+ and Fan1-/mice at 18 months. The area of each nucleus was normalized to the median
nuclear area of each section. Data were then plotted and grouped
according to area. n = 3. Error bars indicate SD. (E) H&E staining of liver
sections from Fan1+/+ and Fan1-/- animals at 3 and 18 months. (F)
Quantification of the area of nuclei in the liver isolated from Fan1+/+ and
Fan1-/- mice at 3 and 18 months. n = 3. Error bars indicate SD.
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Figure 2.14 Liver function, but not kidney function is abnormal in
Fan1-deficient mice.
(A-D) Analysis of serum level of (A) blood urea nitrogen (BUN), (B)
creatinine, (C) phosphorus, and (D) magnesium to monitor kidney function
of Fan1+/+ and Fan1-/- mice at indicated ages. (E-H) Analysis of serum
level of liver enzymes and markers of liver function: (E) alanine
transaminase (ALT), (F) aspartate transaminase (AST), (G) albumin (ALB),
and (H) globulin (GLOB). Bars represent mean ± SD; ***p < 0.001, **p <
0.01 were calculated using F-test.
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Figure 2.15 Karyomegaly is a result of polyploidization.
(A) Representative images of fluorescent in situ hybridization (FISH)
performed with probes against the indicated loci in the kidneys, livers, and
spleens of 18-month-old Fan1-/- animals. The detail of the probes is given
in Section 6.1.16. (B) Quantification of the cells with more than two signals
per nucleus in 18-month-old Fan1-/- animals. The analysis was restricted to
tubular epithelial cells in the kidney and liver hepatocytes. (C-E)
Quantification of FISH signals per nucleus in 18 months old Fan1-/animals. Tubular epithelial cells in the kidney (C), liver hepatocytes (D) and
cells in the spleen (E) were assessed.
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2.3.7 HSCs are unaffected in Fan1-deficient mice when unchallenged but
severely affected when Fan1 mice are treated with MMC
Anemia has been reported in a number of human KIN cases, prompting us
to investigate the possible hematological dysfunction in Fan1-deficient mice. At
the peripheral blood level, Fan1-/- mice did not show obvious signs of cytopenia
at a young age (Figure 2.16A-E). To explore the possibility of bone marrow
abnormalities in Fan1 animals, we analyzed the hematopoietic stem cell (HSC)
population in the bone marrow of young (3 month) and old (18 month) mice with
or without Fan1 deficiency. We could not detect any changes in the level of the
Lineage (Lin)- Sca-1+ c-Kit+ (LSK) or Lin- Sca-1- c-Kit+ (LK) populations
between Fan1+/+ and Fan1-/- mice (Figure 2.17A, B). The numbers of long-term,
short-term, and multipotent HSCs as well as the more differentiated progenitor
cells-(megakaryocyte/erythroid progenitors, granulocyte/monocyte progenitors,
and common myeloid progenitors) in Fan1-/- animals were also similar to that of
the wild-type control in the same age groups (Figure 2.17C, D). Inactivation of
Fan1 in mice with Fancd2 deficiency did not significantly reduce the level of
hematopoietic progenitor cells compared with Fancd2 single-mutant mice (Figure
2.17E, F). Collectively, these results indicated that the activity of FAN1 is not
required for the protection of early HSCs under unstressed conditions.

Although the bone marrow was not functionally compromised in Fan1-/mice, we asked whether FAN1 was required upon exogenous treatment with ICL-
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inducing agents. Fan1-/- and control mice were treated with a single
intraperitoneal injection of 10 mg/kg MMC and were followed over the next 3
weeks. Some wild-type and heterozygous Fan1+/- mice showed a minor drop in
body weight after receiving the MMC. Most eventually regained the initial weight
and tolerated the dose of MMC given until the end of the experiment (20 days
post injection) (Figure 2.18A). In contrast, all Fan1-/- mice reacted acutely to
MMC, displaying a significant drop in body weight (10%–30%) following the
treatment (Figure 2.18A). Ninety percent of Fan1-/- mice tested died within two
weeks after MMC treatment (Figure 2.18B). On day 7 after treatment with MMC,
a parallel cohort of Fan1-/- mice displayed depletion of the hematopoietic
progenitor cells, as shown by a decrease in total cell number in the femurs and a
complete disappearance of c-Kit+ bone marrow cells following MMC treatment
(Figure 2.19A-D). Furthermore, MMC-treatment caused significantly greater
reduction in the level of LSK cells in Fan1-deficient c-Kit+ cells cultured in vitro
compared to wild-type (Figure 2.19E). In agreement, the histological analysis
revealed pronounced hypocellularity in the bone marrow and the thymus of Fan1/- mice (Figure 2.18C). The effect of ICL repair deficiency on the hematopoietic
system of Fan1-/- animals was further supported by significant neutropenia and
thrombocytopenia. Although the red blood cell (RBC) count was largely unaltered
due to the long half-life of RBCs, the reticulocyte counts of Fan1-/- mice was
significantly lower than Fan1+/+ mice at day 7 after MMC treatment (Figure
2.19F-I). These results illustrate the necessity of FAN1 for the maintenance of
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hematopoiesis and survival of animals exposed to high levels of exogenous
crosslink damage.
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Figure 2.16 Blood counts are normal in the majority of Fan1-deficient
mice.
(A-E) Blood analysis in Fan1+/+ and Fan1-/- mice: (A) platelets (PLT), (B)
white blood cells (WBC), (C) red blood cells (RBC), (D) reticulocytes (RET),
and (E) hemoglobin concentration (HGB).
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Figure 2.17 FAN1 is dispensable for the bone marrow maintenance
under unstressed condition.
(A) Representative FACS profiles of HSCs isolated from bone marrow of
Fan1+/+ and Fan1-/- mice, indicating LSK and LK population. (B)
Quantification of hematopoietic stem cells (HSCs) isolated from Fan1+/+
and Fan1-/- mice assessed by FACS. n = 3 per genotype. Error bars
indicate SD. (C) Analysis of LT-HSC, ST-HSC and MPP isolated from
femurs and tibiae of Fan1+/+ and Fan1-/- mice at indicated ages assessed
by FACS. Error bars, s.d., n = 3 per genotype. (D) Analysis of MEP
(megakaryocyte/erythroid

progenitors),

GMP

(granulocyte/monocyte

progenitors), and CMP (common-myeloid progenitors) isolated from femurs
and tibiae of Fan1+/+ and Fan1-/- mice at indicated ages assessed by
FACS. Error bars, s.d., n = 3 per genotype. (E) Quantification of HSCs
isolated from mice of the indicated genotypes, assessed by FACS. n = 3
per genotype. (WT) Wild type. Error bars indicate SD. (F) D) Analysis of LTHSC, ST-HSC, and MPP (left) and MEP, GMP, and CMP (right) isolated
from femurs and tibiae of 6 months old WT, Fan1-/-, Fancd2-/-, and Fan1-/Fancd2-/- mice assessed by FACS. Error bars, s.d., n = 3 per genotype.
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Figure 2.18 Fan1-deficient mice are hypersensitive to MMC.
(A) Weight monitoring of mice after treatment with MMC. Following
intraperitoneal injection of 10 mg of MMC per kg, Fan1+/+, Fan1+/-, and
Fan1-/- mice were weighed every 2 days for 20 days or until death. Weight
is expressed as % of original weight on the day of MMC injection. (B)
Survival of Fan1+/+, Fan1+/-, and Fan1-/- mice (n = 10 per genotype) after
a single treatment with 10 mg/kg MMC. Mice from each genotype were
monitored up to 20 days following MMC intraperitoneal injection. Bone
marrow and thymus histology from Fan1+/+ and Fan1-/- mice treated 1
week prior with 10 mg/kg MMC. Representative images at 10× and 63× are
shown.
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Figure 2.19 FAN1 is required to protect the hematopoietic stem and
progenitor cells from high level of ICL damage.
(A) Total number of cells per femur of Fan1+/+ and Fan1-/- mice untreated
or treated 1 week prior with 10 mg/kg MMC. Bars represent mean ± SD.
(∗∗) P < 0.01, calculated using unpaired t-test. (B) Number of nucleated
cells per femur of Fan1+/+ and Fan1-/- mice untreated or treated 1 week
prior with 10 mg/kg MMC. Bars represent mean ± SD; **p < 0.01 were
calculated using unpaired t-test. (C) Representative FACS profile of bone
marrow cells that were enriched for c-Kit positive population, determined by
FSC and 7-ADD (7-amino-actinomycin D) viability gate. The bone marrow
cells were isolated from Fan1+/+ and Fan1-/- mice untreated or treated 1
week prior with 10 mg of MMC per kg. (D) Percentage of live bone marrow
cells that were enriched for c-Kit+ population. The bone marrow cells were
isolated from Fan1+/+ and Fan1-/- mice untreated or treated 1 week prior
with 10 mg/kg MMC. Bars represent mean ± SD. (∗∗) P < 0.01, calculated
using unpaired t-test. (E) Survival of Fan1+/+ and Fan1-/- LSK population
within the in vitro culture c-Kit+ cells following a single treatment with MMC.
After 48 hours, LSK frequency were determined and normalized to the
untreated control to calculate the percentage of survival. Error bars indicate
SD. (F-I) White blood cell (WBC) (F), platelet (PLT) (G), Red blood cell
(RBC) (H), and Reticulocyte (RET) (I) counts of Fan1+/+ and Fan1-/- mice
untreated or treated 1 week prior with 10 mg/kg MMC. Bars represent mean
± SD. (∗∗) P < 0.01, calculated using unpaired t-test.
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2.3.8 FAN1 is dispensable for the protection of bone marrow against IR
induced damage
To examine whether Fan1 deficiency renders bone marrow sensitivity to
DNA damaging agents in a non-specific manner, we analyzed the effect of
ionizing radiation (IR) on the hematopoietic system in wild-type and Fan1-/animals. Mice were treated with a sublethal dose of 450 cGy X-ray that has been
shown to cause severe bone marrow abnormalities in mice models with defects
in the repair of IR-induced DNA damage (Nussenzweig et al., 1997). The
changes in the peripheral blood cells and hematopoietic stem and progenitor cell
function were monitored to assess the requirement of FAN1 in the protection of
bone marrow against IR-induced lesions. A significant drop in the body weight
among wild-type or Fan1-/- cohorts was not observed within 6 weeks following
the irradiation. However, the body weight of both groups of animals remained
relatively constant until 3 week following the treatment (Figure 2.20A). As
previously described, IR treatment induced significant damage to the bone
marrow progenitor cells, leading to a drastic depletion of WBC, platelets and
reticulocytes level in the peripheral blood analyzed 1 week after the treatment.
The level of red blood cell count reduced more gradually, most likely owing to its
longer half-life. At around week 4-5, most of the blood cell counts in both wildtype and Fan1-/- mice returned back to one observed in the untreated controls
(Figure 2.20B-E). These results indicated that the hematopoietic progenitor cells
were not significantly more damaged in IR-treated Fan1-deficient animals. To
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specifically assess the level of HSCs in the bone marrow, we analyzed the level
of c-Kit+ and LSK cells two weeks following IR treatment and found no significant
alternation in wild-type and Fan1-deficient animals (Figure 2.20F). These results
suggest that FAN1 is dispensable for the repair of IR-inflicted damage and that
its role in the protection of the hematopoietic system is specifically against DNA
crosslinking agents.
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Figure 2.20 Fan1 deficiency does not cause bone marrow sensitivity to
IR.
(A) Weight monitoring of mice after treatment with IR. Following 450 cGy of
x-ray treatment, Fan1+/+ and Fan1-/- mice were weighed every 3 days for 6
weeks. Weight is expressed as % of original weight on the day of
irradiation. (B-E) White blood cell (WBC) (B), platelet (PLT) (C), Red blood
cell (RBC) (D), and Reticulocyte (RET) (E) counts of Fan1+/+ and Fan1-/mice untreated or IR-treated monitored weekly for 6 weeks following IR
treatment. Bars represent mean ± SD. (F) Percentage of live bone marrow
cells that were enriched for c-Kit+ (left) or LSK (right) populations. The bone
marrow cells were isolated from Fan1+/+ and Fan1-/- mice untreated or
treated 2 weeks prior with 450 cGy of x-ray. Bars represent mean ± SD.
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2.4 Summary of the findings
FAN1 expression could not be detected in fibroblasts of human KIN
patient or the Fan1 knockout mouse embryonic fibroblasts that were generated
for the study. Using cells from both species, we showed that FAN1 deficiency
results in cellular sensitivity to ICL-inducing agents. The level of ICL sensitivity in
FAN1-negative cells is significantly lower than cells lacking Fanconi anemia
proteins, suggesting that the ICL repair function of FAN1 and FANC proteins are
not equivalent. Using the Fan1-deficient MEFs, we showed that the UBZ mutant
FAN1 could rescue the proliferation defects and suppress chromosomal
aberration induced by MMC. Therefore, FAN1 can participate in ICL repair
independently of its interaction with the ID2 complex. This finding is also
corroborated by the epistasis analysis, which revealed that FAN1 has FANCD2
independent function in the suppression of MMC-induced chromosomal
abnormalities. When analyzed for the genetic interactions with other ICL repair
nucleases, we found that FAN1 and MUS81 are epistatic, whereas FAN1 is
redundant with SNM1A. The requirement of SNM1A in ICL resistance is only
apparent when FAN1 is co-inactivated, suggesting that FAN1 can substitute for
SNM1A in ICL repair. The SNM1A-redundant function of FAN1 does not depend
on its UBZ domain.

At the whole organism level, Fan1-deficient mice recapitulate the KIN
phenotypes including the presence of renal and liver karyomegaly and liver
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dysfunction, both of which are age-dependent. We showed that the karyomegalic
cells are polyploid, which likely results from genome endoreduplication.
Nevertheless, the renal function was found to be intact even at 18 months of age,
potentially due to the high buffering capacity of the kidney. Fan1-deficient mice
are fertile, display no obvious developmental defects, and show normal bone
marrow function. However, Fan1-deficient hematopoietic tissues including bone
marrow and thymus are sensitive to MMC, with Fan1-/- mice developing MMCinduced bone marrow failure due to hematopoietic stem and progenitor cell
depletion. The dependency of FAN1 in the protection of bone marrow cells is
specific to ICL challenge as ionizing radiation failed to inflict more severe
phenotypes in Fan1-/- than in wild-type animals.
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Chapter 3: Elucidating the impact of aldehyde
detoxification defects on Fan1-deficient mice
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3.1 Introduction
The pathophysiology of KIN disease development is not understood.
Fan1-deficient animals develop KIN characteristics despite being accommodated
in a very controlled environment, with no exposure to exogenous nephrotoxins
(see section 2.3.6) (Airik et al., 2016; Lachaud et al., 2016b; Thongthip et al.,
2016).

Based on this finding, we hypothesize that it is the endogenously

produced toxin that is the culprit in KIN pathogenesis.

Recently, endogenous aldehydes have been shown to contribute to the
pathology of Fanconi anemia, another disorder of ICL repair deficiency
(Garaycoechea et al., 2012; Langevin et al., 2011; Oberbeck et al., 2014; Pontel
et al., 2015). Increased load of acetaldehyde or formaldehyde resulting from
Aldh2 or Adh5 deficiency dramatically exacerbates Fanconi anemia phenotypes
in a mouse model of the disease. Fancd2-/-Adh5-/- mice develop glomerular
diseases and karyomegaly in the kidney (Pontel et al., 2015).

The direct association between the genotoxic effect of formaldehyde on
the kidney and liver tissues in humans has not been widely explored. The toxicity
of formaldehyde and its breakdown product formate is typically attributed to their
effect on the central nervous system and to their potential as carcinogenic agents
(Humans, 2006; Songur et al., 2010). The most direct evidence that
formaldehyde metabolism is critical for the protection of the kidney and liver
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tissues came from the study of Fancd2-/-Adh5-/- mice (see section 1.6.2) (Pontel
et al., 2015). The presence of renal and liver karyomegaly in the double mutant
mice raises a possibility that formaldehyde is a potential in vivo damaging agent
in the kidney and liver.

Another connection between aldehydes and human disease is that
excessive acetaldehyde derived from chronic alcohol consumption causes liver
damage (Chuang et al., 2009; Mills and Harrison, 2005; Seitz and Becker, 2007;
Voigt, 2005). Alcohol consumption has also been shown to compromise the
kidney function by promoting interstitial edema and renal hypertrophy in alcoholfed animals (Epstein, 1997; Van Thiel et al., 1977). Additionally, alcohol-induced
free radical production from the oxidation of acetaldehyde intermediates has
been linked to deterioration of the Na+/K+-ATPase carrier in the proximal tubular
epithelial cells (Laitinen et al., 1991; Parenti et al., 1991; Rodrigo et al., 1991;
Rothman et al., 1992). This phenomenon is potentially linked to the observation
that some chronic alcoholics have increased urinary levels of beta-2microglobulin, N-Acetyl-β-D-glucosaminidase (NAG) and alanine aminopeptidase
(AAP), markers of proximal tubular damage (Jung et al., 1987; Schardijn and
Statius van Eps, 1987). Furthermore, prenatal ethanol exposure has detrimental
effects on postnatal kidney function (De Marchi et al., 1993). Whether any of
these effects on the renal function are derived from ICL damage caused by
ethanol or its acetaldehyde intermediate, remains to be determined.
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Considering the above evidence of potential links between aldehydeinflicted ICL damage and blood, kidney, and liver dysfunction, we set out to test if
increased levels of acetaldehydes or formaldehydes would exacerbate the KIN
phenotypes of Fan1-/- mice. We generated Fan1-/-Aldh2-/- and Fan1-/-Adh5-/double mutant mouse models. We hypothesized that by inactivating Aldh2 or
Adh5, the increased basal level of ICLs may lead to an acceleration or
exacerbation of KIN phenotypes, particularly in Fan1-deficient mice (Figure 3.1).
If acetaldehyde and formaldehyde play a role in KIN pathology, Fan1-/-Aldh2-/or Fan1-/-Adh5-/- double-deficient mice would display worsening of the
phenotypes present in Fan1-deficient mice.
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Figure 3.1 Putative sources of damage that induce KIN in the absence
of FAN1.
The sources of presumed endogenous damage leading to Karyomegalic
Interstitial Nephritis (KIN) is unknown. Formaldehyde and acetaldehyde are
two ICL-inducing agents that have been shown to play a role in the
pathogenesis of Fanconi anemia, which is a disorder of unrepaired ICLdamage. It is possible that these agents would also be deleterious in the
setting of FAN1 deficiency.
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Results
3.2 Generation of Fan1-/-Aldh2-/- and Fan1-/-Adh5-/- mice
To test the hypothesis that lack of detoxification of acetaldehyde or
formaldehyde would exacerbate the phenotypes of Fan1-deficient mice, the
Fan1-/- were crossed with Aldh2-/- or Adh5-/- to generate Fan1+/-Aldh2+/- and
Fan1+/-Adh5+/- double heterozygotes (Figure 3.2A). The double heterozygotes
were crossed to derive Fan1-/-Aldh2-/- or Fan1-/-Adh5-/- double homozygous
mutants (Figure 3.2A). The male and female Fan1-/-Aldh2-/- or Fan1-/-Adh5-/double homozygotes were then used to establish the cohorts of double
homozygotes for subsequent study. In order to enrich animals for the
experiments, we generated WT, or single mutant animals: Fan1-/-, Aldh2-/-, and
Adh5-/- through the crosses from the homozygous parental breeding pairs
(Figure 3.2B).

The crosses between Fan1-/-Aldh2-/- yielded pups at similar ratios to wildtype and Fan1 single mutant breeding pairs, suggesting that deficiency in Aldh2
did not affect the fertility of the male and female Fan1-deficient animals, nor did it
impair embryogenesis or fetal viability (Figure 3.3). Interestingly, loss of ADH5
alone caused a reduction in the number of pups produced in comparison to wildtype animals (Figure 3.3). This was in contrast to the published data, which
revealed no differences in terms of the litter size at weaning (Liu et al., 2004).
The reason for this difference is unclear. Inactivation of Fan1 in Adh5-/- animals
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resulted in further decrease in the litter size compared to Adh5-/- single mutant
(Figure 3.3). Deficiency in Aldh2 did not compromise the growth of mice lacking
Fan1 as Fan1-/-Aldh2-/- DKO displayed normal growth with the 12-weeks weight
comparable to wild-type and Fan1-/- animals. Fan1-/-Adh5-/- on the other hand,
exhibited moderate growth defect when compared with Fan1-/- or Adh5-/- single
mutants (Figure 3.4A, B).
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Figure 3.2 Schematic of mouse interbreeding to generate mice for the
study of the genetic interaction between Fan1 and Aldh2 or Adh5.
(A) The generation of double knockout Fan1-/-Aldh2-/- or Fan1-/-Adh5-/mice for the study. (B) The generation of wild-type (WT) and single
knockout Fan1-/-, Aldh2-/-, or Adh5-/- mice for the study.
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Figure 3.3 Deficiency of Adh5 but not Aldh2 results in reduced pup
numbers per litter in Fan1 mutant mice.
The number of pups per litter produced from the crosses between wild-type
(WT) or Fan1-/-, Aldh2-/- and Adh5-/- single-mutant or Fan1-/-Aldh2-/- and
Fan1-/-Adh5-/- double-mutant breeding pairs. *p < 0.05, ***p < 0.001, ****p
< 0.0001, and n.s., not significant, were calculated by one-way ANOVA.
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Figure 3.4 Deficiency of Adh5 but not Aldh2 results in growth defect in
Fan1-mutant mice.
(A-B) Weight of male (A) and female (B) WT, Fan1-/-, Aldh2-/-, Fan1-/Aldh2-/-, Adh5-/- and Fan1-/-Adh5-/- mice from 12 weeks of age. Error bars,
s.d., *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and n.s., not
significant, were calculated by Mann-Whitney U test.
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3.3 Analysis of the hematopoietic system in mice lacking Fan1 and Aldh2
or Adh5
Aldh2 or Adh5 deficiency did not lead to a significant change in the level of
peripheral blood cells irrespective of Fan1 status and age (Figure 3.5A-H). We
next assessed the state of the hematopoietic system in mice with deficiency in
FAN1 and aldehyde detoxification enzymes by analyzing the level of LSK (LinSca1+ cKit+) population in of Fan1-/-Aldh2-/- and Fan1-/-Adh5-/- mice and the
appropriate corresponding controls. We found that Adh5 but not Aldh2 deficiency
led to a significant reduction of the LSK population of 3 months old mice under
Fan1-deficient background (Figure 3.6A). The 12 months old Fan1-/-Aldh2-/- and
Fan1-/-Adh5-/- mice, however, displayed wild-type level of LSK population
(Figure 3.6B).

In order to assess the functionality of HSCs, we adopted the competitive
repopulation assay to quantify the engraftment potential of the HSCs from WT,
Fan1-/-,

Aldh2-/-,

Fan1-/-Aldh2-/-,

Adh5-/-,

Fan1-/-Adh5-/-

animals.

The

transplant was performed from the donor with CD45.2 isotype into the congenic
recipients with CD45.1 isotype pre-conditioned with lethal dosage of 850 cGy of
x-ray. By quantifying the frequency of CD45.2/CD45.1 ratio of the leukocytes in
the recipient animals, we were able to derive the engraftment efficiency of HSCs
under various combined genetic backgrounds at 1, 2 and 4 months posttransplant as previously described (Katayama et al., 1999; Morrison et al., 1996).
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The primary transplant revealed that the engraftment potential was not
compromised in Fan1-deficient mice (Figure 3.7A-C). Furthermore, inactivating
Aldh2 or Adh5 did not affect the engraftment of long term HSCs (LT-HSCs) after
a single transplantation cycle (Figure 3.7A-C). We further challenged the HSCs
by performing the second round of bone marrow transplant using the total bone
marrow isolated from the primary recipients two months post-transplant and
transferred into the secondary recipients that were also pre-conditioned with xray. Notably, mice lacking FAN1 displayed poorer engraftment compared to WT
control after the secondary transplant experiment (Figure 3.8). This observation
supports the conclusion that FAN1 is required for the protection of HSCs under
stressed condition (Section 2.3.7). Aldh2 deficiency also led to a significant
reduction in the engraftment potential of HSCs in the secondary transplant
(Figure 3.8) but Aldh2 deficiency did not exacerbate the defect in engraftment in
Fan1-deficient animals.

We next assessed whether deficiency in either of the aldehyde
detoxification enzyme would lead to an increase in the DNA damage level
manifested as micronuclei in the peripheral RBC or RET. The level of
micronucleated RBC (MN-RBC) and micronucleated RET (MN-RET) based on
positive propidium iodine (PI) staining did not increase in Fan1-/-Aldh2-/- or
Fan1-/-Adh5-/- animals in comparison to the wild-type or single mutant controls.
This leads us to conclude that FAN1 is dispensable for the protection of the
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erythropoietic compartment from micronuclei formation under wild-type or
acetaldehyde/formaldehyde-detoxification deficient conditions (Figure 3.9A-C).
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Figure 3.5 Deficiency of Fan1 in combination with Aldh2 or Adh5 does
not cause abnormality in the level of peripheral blood cells.
(A-H) Blood analysis mice of indicated genotypes at 3 months (A-D) or 12
months (E-H) of age: (A/E) platelets (PLT), (B/F) white blood cells (WBC),
(C/G) red blood cells (RBC), (D/H) reticulocytes (RET). Error bars, s.d.,
n=3.
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Figure 3.6 Deficiency of Adh5 but not Aldh2 compromises HSC
maintenance in 3 months old Fan1-mutant mice.
(A-B) Quantification of HSCs isolated from 3 months (A) or 12 months (B)
WT, Fan1-/-, Aldh2-/-, Fan1-/-Aldh2-/-, Adh5-/- and Fan1-/-Adh5-/- mice
assessed by FACS. Error bars, s.d., n=6 for (A) and n=3 for (B) per
genotype. *p < 0.05 and ***p < 0.001 were calculated by one-way ANOVA.
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Figure 3.7 Loss of ALDH2 or ADH5 does not affect the engraftment
potential of Fan1-deficient mice following primary transplant.
(A-C) Quantification of HSC function based on percent engraftment of
CD45.2 donor bone marrow cells over the CD45.1 competitor bone marrow
cells following the primary transplant calculated by the percent of CD45.2
donor leukocytes (CD45.2/D45.2+CD45.1 or Total reconstitution) of donor
mice of different genotypes relative to the percent of CD45.2 donor
leukocytes of WT analyzed at 4-weeks (A), 8-weeks (B), or 12-weeks (C)
after the transplant. The number of sample (n) is shown in the figure.
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Figure 3.8 Loss of FAN1 or ALDH2 results in reduced engraftment
potential of Fan1-deficient mice following the secondary transplant.
Quantification of HSC function based on percent engraftment of CD45.2
donor bone marrow cells over the CD45.1 competitor bone marrow cells
following the secondary transplant. Percentage of CD45.2 donor leukocytes
(CD45.2/D45.2+CD45.1) of donor mice of different genotypes relative to the
percent of CD45.2 donor leukocytes of WT at 8-weeks after the transplant is
shown. The number of sample (n) was as described in the figure. *p < 0.05
and **p < 0.01 were calculated by one-way ANOVA.
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Figure 3.9 Deficiency of Fan1 and Aldh2 or Adh5 causes insignificant
increase in DNA damage in blood cells as assessed by micronuclei in
normochromatic erythrocytes and reticulocytes.
(A) Representative FACS profiles of micronucleated (PI+) or nonmicronucleated (PI-) normochromatic erythrocytes (MN-NCE) (CD71-) or
Reticulocytes (RET) (CD71+) cells isolated from blood. (B-C) Percent of
MN-NCE (B) or MN-RET analyzed in blood collected from mice of indicated
genotypes.
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3.4 Analysis of the liver and kidney function of mice lacking Fan1 and
Aldh2 or Adh5
In order to assess the impact of concomitant loss of FAN1 and aldehyde
detoxifying enzymes on the pathogenesis of KIN in mice, we monitored the level
of karylomegaly and function of the kidney and liver in aging cohorts at 3 months
and 12 months of age.

As expected from our earlier study, karyomegaly is

absent from kidney or liver tissue at 3 months of age (Figure 3.10A,B). Additional
inactivation of either Aldh2 or Adh5 in Fan1-deficient cohorts did not result in
significant increase in the proportion of karyomegalic nuclei in either tissues
(Figure 3.10A,B). Karyomegaly was apparent in 12 months-old Fan1-/- animals,
but we did not observe an additional increase in the level of enlarged nuclei when
Aldh2 or Adh5 was inactivated in Fan1-/- mice (Figure 3.11). Furthermore, the
kidney from Fan1-/-Aldh2-/- and Fan1-/-Adh5-/- mice did not show signs of
increased level of DNA damage as determine by γH2AX staining or increased
level of proliferating cells as marked by Ki67 (Figure 3.12A, B). However, we did
not observe a significant difference in the level of γH2AX positive staining of
renal tubular epithelium between wild-type and Fan1-/- animals as reported in
(Lachaud et al., 2016b) (Figure 3.12B). It is unclear why this discrepancy exists.
It is possible that presence of the nuclease-inactive FAN1 in the other mosue
model leads to different cellular effects than complete lack of FAN1.
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In parallel to the histological study, we monitored the function of kidney
and liver of Fan1 mice lacking ALDH2 or ADH5 by analyzing the serum level of
their corresponding enzyme and metabolite markers. Again, we failed to notice
any significant changes in the serum level of liver enzymes or liver-produced
proteins as well as the serum markers of the kidney function such as BUN,
creatinine, Mg and Phosphorus (Pi) in Fan1-/-Aldh2-/- or Fan1-/-Adh5-/- mice
(Figure 3.13A-H).

108

Figure 3.10 Kidney and liver karyomegaly are absent from mice
lacking Fan1 and Aldh2 or Adh5.
(A-B) Quantification of the nuclear area (cross-sectional area) of tubular
epithelial cells (A) or liver hepatocyte (B) in the cortex of kidney from mice
of indicated genotypes at 3 months. The area of each nucleus was
normalized to the median nuclear area. Data were then plotted and grouped
according to area (n=3, Error bars, s.d.).
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Figure 3.11 Karyomegaly in Fan1-/- animals is not enhanced by
deficiency of Aldh2 or Adh5.
Quantification of the nuclear area (cross-sectional area) of tubular epithelial
cells in mice of indicated genotypes at 12 months. The area of each nucleus
was normalized to the median nuclear area of each section. Data were then
plotted and grouped according to area (n=3, Error bars, s.d.).
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Figure 3.12 Deficiency of Fan1 alone or in combination with Aldh2 or
Adh5 did not cause an increase in the level of proliferating cells or
cells with DNA damage.
(A-B) Representative images of Ki67- or Ki67+ (A, top) or γH2AX- or
γH2AX+ (B, top) renal tubular epithelial cells and the quantification of Ki67+
(A, bottom) or γH2AX+ (B, bottom) renal tubular epithelial cells in mice of
indicated genotypes at 12 months. The quantification was performed in a
blinded manner from 35-45 high power field (HPF) (40x) images. Error bars,
s.d., n=3 per genotype.
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Figure 3.13 Deficiency of Aldh2 or Adh5 did not cause liver and kidney
dysfunction in young Fan1-deficient mice.
(A-D) Analysis of serum level of (A) blood urea nitrogen (BUN), (B)
creatinine, (C) phosphorus, and (D) magnesium to monitor kidney function
in mice of indicated genotypes at 3-6 months. (F-I) Analysis of serum level
of liver enzymes and markers of liver function: (F) alanine transaminase
(ALT), (G) aspartate transaminase (AST), (H) albumin (ALB), and (I)
globulin (GLOB) in mice of indicated genotypes at 3-6 months. Bars
represent mean ± SD.
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3.5 Impact of alcohol treatment on mice lacking Fan1 and Aldh2 or Adh5
One of the possible explanations for the lack of significant exacerbation of
KIN phenotypes in Fan1-deficient mice lacking ALDH2 or ADH5 is that the
increase in the basal level of acetaldehyde or formaldehyde was below the
threshold required to elicit sufficient damage that would necessitate the repair
activity of FAN1. To further enhance the level of aldehyde-inflicted damage, we
performed alcohol feeding experiments in the Aldh2 or Adh5-deficient animals.
Metabolism of ethanol leads to the formation of acetaldehyde intermediate
whereas the metabolism of methanol leads to the generation of formaldehyde.
Therefore, the administration of ethanol or methanol in mice lacking the
corresponding aldehyde detoxifying enzyme should elicit a greater level of
damage. This is the case with the Fanconi anemia mouse models, as ethanol or
methanol ad libitum feeding leads to stronger hematopoietic defect in Aldh2-/- or
Adh5-/- mice lacking FANCD2 respectively (Langevin et al., 2011; Pontel et al.,
2015). If either of the two aldehydes contribute to the pathogenesis of KIN, this
strategy could expose the phenotypes previously hidden in the untreated Fan1-/Aldh2-/- or Fan1-/-Adh5-/- double mutant mice.

3.5.1 Short-term ethanol exposure of Fan1/Aldh2 mice
To test the effect of ethanol-induced acetaldehyde in the expression of
KIN phenotypes, we employed two separate ethanol treatment schemes. In the
first regimen, ethanol was added to the drinking water at a final concentration of
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15% for 5 days before being changed to 20% for another 5 days. The second
treatment scheme involved supplying 10% of ethanol in the drinking water for
one month. With the high dose treatment of ethanol, the animals lacking ALDH2
regardless of Fan1 status exhibited severe sensitivity with their weight being
drastically reduced to around 80% of the original weight by day 10 of the
treatment (Figure 3.14A, B).

High-dose ethanol treatment regimen resulted in a significant deficiency in
hematopoiesis following ethanol feeding in Aldh2-deficient animals. There was a
reduction in the level of WBC and RET (reticulocytes) in the treated Aldh2-/- and
Fan1-/-Aldh2-/- mice, suggesting that hematopoietic progenitors are negatively
affected by ethanol-induced acetaldehyde (Figure 3.15A, B). Fan1-/-Aldh2-/displayed a greater reduction in the WBC and RET levels then the Aldh2-/- mice
alone. However, only the difference in the reticulocyte count between Aldh2-/single mutant and Fan1-/-Aldh2-/- double mutants were statistically significant
(Figure 3.15B). The level of RBC was unchanged most likely due to their longer
half-life compared to other types of blood cells (Figure 3.15C). The level of
platelets went up significantly in Aldh2-/- and Fan1-/-Aldh2-/- (Figure 3.15D). The
cause of thrombocytosis (high platelet count) was unclear, albeit this trend was in
contrast to the commonly known effect of ethanol in promoting thrombocytopenia
symptom in human with alcoholism (Ballard, 1997; Girard et al., 1987).

115

Ethanol treatment led to a significant depletion of the LSK population in
Aldh2-/- and Fan1-/-Aldh2-/- animals (Figure 3.15E). However, the difference in
the LSK frequencies between Aldh2-/- and Fan1-/-Aldh2-/- was not statistically
significant. We conclude that the absence of Aldh2 was driving hematopoietic
defect following high dose of ethanol treatment. Furthermore, we were able to
detect a significant increase in the level of micronucleated normochromatic
erythrocytes (MN-NCE) in Aldh2-/- and Fan1-/-Aldh2-/- animals compared to
wild-type or Fan1-/- mutant mice (Figure 3.15F). Yet again, the difference
between the micronuclei level of Aldh2-/- and Fan1-/-Aldh2-/- was not statistically
significant, indicating that the observed DNA damage phenotype was caused by
deficiency in Aldh2 not Fan1. With these results, we can conclude that the
ethanol-induced damage on the hematopoietic system in the Fan1/Aldh2 cohorts
was primarily driven by the absence of Aldh2 not Fan1.
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Figure 3.14 Aldh2-deficient mice displayed ethanol sensitivity.
(A) Schematic of ethanol treatment regimen. Mice were treated with 15%
ethanol for 5 days and 20% for another 5 days before being sacrificed for
analysis. (B) Weight of mice measured after the ethanol treatment scheme
in (A). Weight is expressed as % of original weight before the treatment.
Bars represent mean ± SD.
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Figure 3.15 Short-term ethanol treatment affects the hematopoietic
system in Aldh2-deficient mice. Fan1-/-Aldh2-/- animals have slight
decrease in the reticulocyte counts compared to Aldh2-/- animals.
(A-D) White blood cell (WBC) (A), Reticulocyte (RET) (B), Red blood cell
(RBC) (C), and platelet (PLT) (D) counts from mice of indicated genotypes
after the ethanol treatment (Figure 3.12A). Bars represent mean ± SD; *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n.s., not significant were
calculated by one-way ANOVA. (E) Quantification of HSCs isolated from 3month-old mice of indicated genotypes treated with ethanol as in (A-D)
assessed by FACS. Error bars, s.d., n=3. **p < 0.01, ***p < 0.001, n.s., not
significant, were calculated by one-way ANOVA. (F) Percent of total MN
(MN-NCE + MN-RET) analyzed in blood collected from mice of indicated
genotypes treated with ethanol as in (A-D). Error bars, s.d., n=3. *p < 0.05,
**p < 0.01, n.s., not significant, were calculated by one-way ANOVA.
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3.5.2 Long-term ethanol exposure for Fan1/Aldh2 mice
To assess the effect of increased acetaldehyde production in the
Fan1Aldh2 cohorts over longer treatment time, drinking water was replaced with
10% ethanol solution for 1 month (Figure 3.16A). At week 4, mice with deficiency
in Aldh2 lost weight to 80% of the starting weight (Figure 3.16B). The use of
reduced ethanol concentration caused a mild increase in the level of RET and
PLT in mice lacking Aldh2. This was likely a prolonged response to ethanolinduced anemia. However, the differences in the RET and PLT levels between
Aldh2-/- single mutants and Fan1-/-Aldh2-/- double mutants were not statistically
significant. (Figure 3.17A, B). The differences in the level of WBC and RBC
counts between Fan1Aldh2 cohorts were not statistically significant (Figure
3.17C, D).

Next, we analyzed the histology of kidney and liver under long-term
ethanol treatment. We did not detect a significant difference in the number of
karyomegalic nuclei in kidney epithelial or liver cells among mice regardless of
Fan1 and Aldh2 status (Figure 3.18A, B). The ethanol-treated Fan1-/-Aldh2-/double mutant mice displayed normal kidney and liver functions compared to WT
and single mutant animals (Figure 3.19A-H). Additionally, we did not detect an
increase in the level of Ki67+ renal tubular epithelial cells in the alcohol treated
kidney irrespective of Fan1 or Aldh2 status (Figure 3.18C), indicating that the
ethanol treatment employed in the study did not stimulate cell division in the
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kidney tissue as was reported with the treatment with crosslink-inducing agent
cisplatin (Airik et al., 2016).
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Figure 3.16 Aldh2-deficient mice lose more weight after four weeks of
ethanol treatment.
(A) Schematic of ethanol treatment scheme. Mice were treated with 10%
ethanol for 4 weeks, and then sacrificed for analysis. (B) Weight of mice
measured weekly after the ethanol treatment scheme in (A). Weight is
expressed as % of original weight before the treatment.
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Figure 3.17 Long-term ethanol treatment moderately affects the
hematopoietic

system

in

Aldh2-deficient

mice.

No

significant

differences between the peripheral blood cell levels in Aldh2-/- and
Fan1-/-Aldh2-/- deficient animals.
(A-D) Platelet (PLT) (A), Reticulocyte (RET) (B), Red blood cell (RBC) (C),
and white blood cell (WBC) (D) counts from mice of indicated genotypes
after the ethanol treatment (Figure 3.14A). Bars represent mean ± SD; *p <
0.05, **p < 0.01, n.s., not significant was calculated by one-way ANOVA.
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Figure 3.18 Long-term ethanol treatment did not increase the level of
kidney and liver karyomegaly in Fan1/Aldh2 double-deficient mice.
(A-B) Quantification of the nuclear area of tubular epithelial cells (A) or liver
hepatocyte (B) in the cortex of kidney from 4 months old mice of indicated
genotypes at 1 month after the ethanol treatment (Figure 3.14A). The area
of each nucleus was normalized to the median nuclear area. Data were
then plotted and grouped according to area (n=3, Error bars, s.d.). (C) The
quantification of Ki67+ tubular epithelial cells after the alcohol treatment as
in (Figure 3.14A) performed in a blinded manner from 35-45 high power
field (HPF) (40x) images. Error bars, s.d., n=3 per genotype.
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Figure 3.19 Long-term treatment with ethanol did not cause liver and
kidney dysfunction in Fan1/Aldh2 -deficient mice.
(A-D) Analysis of serum level of (A) blood urea nitrogen (BUN), (B)
creatinine, (C) phosphorus, and (D) magnesium to monitor kidney function
in 4 months mice of indicated genotypes after 1 months of ethanol
treatment. (F-I) Analysis of serum level of liver enzymes and markers of
liver function: (F) alanine transaminase (ALT), (G) aspartate transaminase
(AST), (H) albumin (ALB), and (I) globulin (GLOB) in 4 months mice of
indicated genotypes after 1 months of ethanol treatment. Bars represent
mean ± SD.
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3.6 Summary of the findings
Concomitant lack of Aldh2 in Fan1 did not affect growth or fertility of the
animals. In contrast, Fan1/Adh5 double deficiency caused significant growth
defect and reduced number of pups produced per litter. This result underlines a
possible requirement of FAN1 to counteract the damage inflicted by increased
formaldehyde due to the absence of ADH5 to maintain normal growth and
embryonic development. The LSK population in 3 month-old Fan1/Adh5 double
mutant animals was decreased compared to levels in wild-type animals, however
the remaining level of LSK in Fan1-/-Adh5-/- was sufficient to support the
production of peripheral blood cells. The reduction in LSK level was not observed
in Fan1-/-Adh5-/- animals at 12 months. This could be due to an age-related
increase in the cycling activity of hematopoietic stem cells as previously reported
(Rossi et al., 2007). Deficiency of Fan1 alone or in combination with Aldh2 or
Adh5 did not result in reduced engraftment potential after the first transplant.
Secondary transplant revealed that combination of Aldh2 and Fan1 deficiency
resulted in decreased HSC engraftment. Secondary engraftment was not yet
tested in Fan1-/-Adh5-/- animals.

We did not observe a significant increase in the level of karyomegaly in
the kidney or liver tissues in 3 month-old animals lacking FAN1 and ALDH2 or
ADH5. FAN1 status appeared to be a determinant on the level of renal
karyomegaly in 12 months old animals as the deficincy of Aldh2 or Adh5 did not
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lead to increased karyomegaly in kidney or liver. In line with tissue histology, the
concomitant absence of FAN1 and ALDH2 or ADH5 did not cause further
functional decline in the kidney and liver. When treated with ethanol, lack of
FAN1 caused a stronger peripheral blood abnormality in Aldh2-deficient animals,
although the severity was much less compared to that observed in Fancd2/Aldh2
double-mutant animals (Langevin et al., 2011). This result suggests that FAN1
functions in the repair of ethanol-induced damage in the bone marrow, although
to a lesser extent than the proteins of the Fanconi anemia pathway. The ethanol
treatment failed to exacerbate kidney and liver karyomegaly phenotype in Fan1-/or Fan1-/-Aldh2-/- double-deficient animals in our experiments suggesting that
acetaldehyde may not be the endogenous agent that leads to karyomegaly in the
absence of FAN1.

Experiments with methanol treatment of Fan1-/-Adh5-/-

animals will be necessary to further assess possible role of increased
formaldeyde levels on the pathogenesis of karyomegalic interstitial nephritis.

Overall our data highlight the fact that increased level of formaldehyde but
not acetaldehyde could moderately compromise the maintenance of HSC level in
young Fan1-deficient animals. However, under stressed condition, for instance
through successive bone marrow transplantations, the presence of FAN1 or
ALDH2 is necessary for the protection of HSCs from the transplant-induced
stress. In terms of the KIN phenotypes, we conclude that the heightened level of
endogenous acetaldehyde or formaldehyde present due to Aldh2 or Adh5
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deficiency, is insufficient to enhace the level of tissue karyomegaly or to incite
kidney and liver dysfunctions in Fan1-deficient animals. Acetaldehyde and
formaldehyde are unlikely to be the endogenous sources of damage that
promote KIN-associated phenotypes in the absence of FAN1.
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Chapter 4: Interplay between the Fanconi anemia
pathway and non-homologous end joining in ICL
repair
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4.1 Introduction
Several recent studies suggest that ICL sensitivity and genomic instability,
two major hallmarks of Fanconi anemia are a result of inappropriate repair
activity of another DNA repair pathway, the non-homologous end joining (NHEJ).
It was shown that suppression of NHEJ could rescue ICL hypersensitivity and
chromosomal aberration in FA-deficient cells in multiple model organisms
(Adamo et al., 2010; Bouwman et al., 2010; Pace et al., 2010). There are;
however, a number of conflicting reports among the results from different model
systems, with paucity of data from the human Fanconi anemia patient cells
(reviewed in (Kottemann and Smogorzewska, 2013). This prompted us to
analyze whether inactivating NHEJ can suppress ICL repair defects in FA patient
cells.

4.1.1

Double

strand

break

repair

pathway

choice:

homologous

recombination (HR) vs non-homologous end joining (NHEJ)
DSBs are repaired by one of two repair processes – homologous
recombination (HR) or non-homologous end joining (NHEJ). Several FA proteins,
including BRCA1/FANCS, BRCA2/FANCD1, PALB2/FANCN, RAD51/FANCR
and SLX4/FANCP, are key regulators of important steps during the process
(Howlett et al., 2002; Vaz et al., 2010; Wang et al., 2015; Xia et al., 2007).
BRCA1 is required for the resection of DSB, to promote HR by preparing DNA
ends for the BRCA2-dependent loading of RAD51. RAD51, a recombinase,
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forms RAD51-ssDNA nucleoprotein filaments to facilitate homology search and
strand invasion. Some of the D-loop structures formed following the strand
invasion can be resolved by SLX4-associated nucleases SLX1 and MUS81
(Garner et al., 2013; Li and Heyer, 2008; Wyatt et al., 2013). In addition, FA
proteins of the core and the ID2 complexes have been shown to have a
modulatory role in the control of HR proficiency, although the mechanism is still
unclear (Nakanishi et al., 2005; Smogorzewska et al., 2007). Homology directed
repair is considered to be an error-free process since the template for the repair
is a sister chromatid.

In the NHEJ pathway, DSB ends are captured by the Ku70/80
heterodimers (Blier et al., 1993; Falzon et al., 1993; Mimori and Hardin, 1986).
DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a serine/threonine
kinase is recruited and its kinase activity promotes endonucleolytic processing of
DSB ends by Artemis and subsequent ligation by DNA Ligase IV (LIG4)/XRCC4
complex with the help of a stimulatory factor XLF (Ciccia and Elledge, 2010;
Goodarzi et al., 2006; Grawunder et al., 1997; Yannone et al., 2008). The
endonucleolytic processing and the ability of NHEJ machinery to directly rejoin
two broken DNA ends together regardless of the sequence homology, make the
repair outcome error-prone, leading to accumulation of genomic mutations and
chromosomal translocations (Chiruvella et al., 2013; Lieber, 2008, 2010).
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4.1.2 Aberrant NHEJ is implicated in causing genome instability in Fanconi
anemia
The repair of ICL-induced DSBs generated by ICL unhooking have been
shown to depend on homologous recombination (Long et al., 2011). This
preference for repair via HR instead of NHEJ is thought to be a consequence of
the activity of FA pathway and HR during S/G2 phases (Moore and Haber, 1996;
Sonoda et al., 2006), as well as the type of substrate that is created during ICL
repair. Recent studies suggest the FA pathway may play an active role in
inhibiting aberrant NHEJ activity at the ICL-induced DSBs and protect cells from
accumulating chromosomal abnormalities (Adamo et al., 2010; Pace et al., 2010;
Zhang et al., 2016). Suppression of NHEJ has been shown to relieve ICL
sensitivity in a number of FA-deficient model systems. In Caenorhabditis elegans
with a germline defects in fcd-2 (FANCD2), sensitivity to crosslinking agents and
abnormal meiotic crossovers can be ameliorated after the deletion of lig-4
(Adamo et al., 2010). A knockout of Ku70 in FANCC-deficient DT40 chicken cells
as well as depletion of Ku80 in human FA-D2 or FA-C patient cells using RNAi
also result in a partial rescue of ICL hypersensitivity (Adamo et al., 2010; Pace et
al., 2010). Furthermore, treatment with DNA-PKcs inhibitor fully or partially
alleviated sensitivity to ICL-inducing compounds in FANCA or FANCD2-depleted
human HeLa cells and Fanca or Fancc mutant mouse embryonic fibroblasts
(MEFs). Depletion of FANCD2 failed to sensitize DNA-PKcs-deficient M059J
human glioblastoma cells to ICL-inducing agents (Adamo et al., 2010). More
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recently, inhibition of TGF-β signaling was shown to promote ICL resistance of
FA patient cell lines and to suppress hematopoietic stem cell (HSC) defects in FA
mouse and human cells. This inhibition was correlated with up-regulation of HR
factors and down-regulation of NHEJ factors (Zhang et al., 2016).

The finding of NHEJ inhibition rescuing phenotypes of Fanconi anemia
deficiency, raised a number of interesting questions. One would want to know
the mechanism of how the FA pathway functions to counteract the inappropriate
engagement of NHEJ proteins and a more profound question of how the ICL
repair proceeds in the absence of FA and NHEJ pathways. Mutagenicity of such
a process would be of interest.

Therapeutically, it would be important to

determine whether NHEJ inhibition could be a potential medical treatment for the
patients with Fanconi anemia, even in the short term while a patient is awaiting a
bone marrow transplant, and whether the effect of NHEJ inhibition is specific to
particular crosslinking agents, or complementation groups of FA patients.

The implication that NHEJ underlies the ICL sensitivity and chromosomal
aberration in FA-deficient cells has, however, been challenged by contradicting
results of other studies. Knockout of LIG4 or DNA-PKcs does not rescue of
crosslink sensitivity in DT40 cell lines (Pace et al., 2010). In very convincing
genetic knockout studies, MEFs lacking FANCD2 and Ku80, DNA-PKcs, or
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53BP1 were as sensitive to ICL-inducing agents as FANCD2-deficient cells alone
(Bunting et al., 2012; Houghtaling et al., 2005).

The disparity between results of different studies that assessed the
genetic interaction of FA and NHEJ pathways prompted our studies that use
human patient cell lines. In this study, we assessed whether disrupting
components of NHEJ with chemical inhibitors, RNAi or CRISPR-Cas9 could
rescue the ICL hypersensitivity of human FANCA-/- patient fibroblasts. All of our
experiments led to a conclusion that abrogation of major NHEJ factors does not
alleviate crosslink repair defect phenotypes of FANCA-/- cells.
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Figure 4.1 Schematic showing proteins in the non-homologous end
joining pathway.
Ku70/Ku80 heterodimer complex recruited to DSB ends activates DNAPKcs. In parallel, 53BP1 is recruited to promote NHEJ by suppressing
extensive DNA end resection and enhancing DNA end mobility. DNA-PK
regulates the stability of DSB ends through phosphorylation of Artemis and
other protein substrates. Artemis facilitates DNA end processing and,
subsequently, LIG4/XRCC4 complex and XLF catalyze the ligation of the
broken ends to complete NHEJ repair.
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Results
4.2 Inactivation of DNA-PKcs does not rescue MMC-induced proliferation
defects in cells lacking FA pathway function.
FANCA-/- (RA3087) human patient fibroblasts with biallelic deletion of
FANCA (Kim et al., 2013), were used for studies to examine whether
suppressing essential NHEJ factors could rescue crosslink repair defects in FA
patient cells. We first used RNAi-mediated knockdown to deplete DNA-PKcs in
RA3087 cells (Figure 4.2A). Three independent hairpins to DNA-PKcs efficiently
suppressed NHEJ activity as determined by increased sensitization of shDNAPKcs expressing RA3087 cells to ionizing irradiation (IR) (Figure 4.2A, B).
However, these cells were still as sensitive to MMC as the control FANCA-/- cells
expressing control shRNA (Figure 4.2C). We next chemically inhibited DNA-PKcs
activity in RA3087 cells using DNA-PKcs inhibitors. Both DNA-PKcs inhibitors,
NU7026 and NU7441, efficiently inhibited NHEJ as demonstrated by dosagedependent IR-induced survival defect in inhibitor-treated RA3087 cells (Figure
4.2D). RA3087 cells treated with the inhibitors at dosages that induced NHEJ
suppression without significant growth defects (10 μM for NU7026 or 1 μM for
NU7441) did not exhibit resistance to MMC (Figure 4.2E, F). DNA-PKcs inhibitor
NU7026 treatment also failed to reduce MMC sensitivity of FA patient cells
lacking FANCD2 or SLX4, FA proteins that act downstream of FANCA (Figure
4.2G). These results show that shRNA-depletion or chemical inhibition of DNA-
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PKcs to inactivate NHEJ did not restore crosslink repair proficiency in FA patient
cells.
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Figure 4.2 Suppression of DNA-PKcs does not rescue MMC sensitivity
in FANCA-deficient cells.
(A) Survival of RA3087 FANCA-deficient patient cells stably transduced with
shRNA targeting Luciferase (control) or DNA-PKcs after IR treatment (0-8
Gy). FA-A patient cells with siRNA treatment against ATM was used as IR
sensitive-control. Error bars, s.d.. (B) Survival of RA3087 cells stably
transduced with shRNA targeting Luciferase (control) or DNA-PKcs and
RA3087 cells complemented with FANCA after MMC treatment (0-100 nM).
Error bars, s.d.. (C) Immunoblot showing the expression of DNA-PKcs in
the shRNA transduced RA3087 cells used in A and B. (D) Survival of
RA3087 cells under untreated or treated with 2 Gy IR after the pretreatment
with NU7026 (0-10 μM) or NU7441 (0-10 μM). Error bars, s.d.. (E) Survival
of RA3087 cells stably transduced with empty vector or with FANCA under
chronic treatment with MMC (0-100 nM). The cells were pretreated with 10
μM NU7026 or DMSO. Error bars, s.d.. (F) Survival of RA3087 cells stably
transduced with empty vector or with FANCA after treatment with MMC (0100 nM). The cells were pretreated with 1 μM NU7441 or DMSO. Error
bars, s.d.. (G) Survival of wild type fibroblasts (BJ), RA2645 FANCD2deficient cells, RA3331 SLX4-deficient cells after treatment with MMC (0100 nM). The cells were pretreated with 10 μM NU7026 or DMSO. Error
bars, s.d..
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4.3 Inactivation of DNA Ligase IV or DNA Ligase III does not rescue MMCinduced proliferation defects in cells lacking FA pathway
We next examined whether suppression of DNA Ligase IV would rescue
ICL hypersensitivity in FANCA-deficient cells. FANCA depletion in LIG4+/+,
LIG4+/-, or LIG4-/- HCT116 cell lines (Oh et al., 2013) led to a significant
reduction

of

FANCA

protein

level

and

a

disappearance

of

FANCI

monoubiquitination in all shFANCA transduced HCT116 cell lines, indicating a
successful inhibition of the FA pathway. FANCA depletion in all cell lines,
regardless of the LIG4 status resulted in no change to MMC sensitivity from the
parental cell lines expressing control shRNA (Figure 4.3A, B), leading to
conclusion that absence of Ligase IV could not rescue sensitivity to MMC in the
setting of FA pathway deficiency. We have noted, however, that cells lacking
one allele of LIG4 were more sensitive to MMC than the LIG4+/+ HCT116 cells
and that the LIG4-/- HCT116 were even more sensitive than the LIG4+/- HCT116
cells. This finding will have to be confirmed in other, non-HCT116 cells.

In parallel, we assessed impact of DNA Ligase III deficiency on MMC
sensitivity in the setting of FANCA deficiency. Ligase III function is essential in
mitochondria (Simsek et al., 2011). To examine the impact of LIG3 and
alternative NHEJ suppression on the outcome of ICL repair in FA-deficient cells,
we used FANCA shRNAs in HCT116 cell lines with LIG3 being inactivated in the
nucleus but active in the mitochondria (Jones et al., 2014; Oh et al., 2014).
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Absence of nuclear LIG3 did not rescue the MMC sensitivity of FANCA-depleted
HCT116, indicating that alternative end joining pathway is unlikely to be
responsible for ICL-inflicted genomic instability in cells deficient in FA pathway
(Figure 4.3C, D).
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Figure 4.3 LIG4 or LIG3 inactivation does not rescue MMC sensitivity
in the setting of FANCA depletion.
(A) Survival of LIG4+/+, LIG4+/-, and LIG4-/- HCT116 cells stably
transduced with shRNA targeting Luciferase (control) or FANCA after MMC
treatment (0-75 nM). Error bars, s.d.. (B) Immunoblot showing expression of
FANCA and FANCI in the shRNA transduced cells used in A with or without
24 hours 1 μM MMC treatment. (C) Survival of LIG3+/+, LIG3-/-, LIG3-/+WT LIG3, and LIG3-/- +ΔBRCT LIG3 HCT116 cells stably transduced with
shRNA targeting Luciferase (control) or FANCA after MMC treatment (0-75
nM). Error bars, s.d.. (D) Immunoblot showing expression of FANCA and
FANCI in the shRNA cells used in C with or without 24 hours 1 μM MMC
treatment.
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4.4 Inactivation of DSB repair choice factor, 53BP1, does not rescue MMCinduced proliferation defects in FANCA-/- cells
We next assessed if 53BP1, factor that functions upstream of the core
NHEJ machinery to promote the choice between NHEJ and HR in DNA DSB
repair, would rescue MMC sensitivity of FANCA-/- cells. There are conflicting
reports on whether 53BP1 inactivation could rescue the ICL-repair defect in
BRCA1-deficient mouse cells (Bouwman et al., 2010; Bunting et al., 2012).
Notably, 53BP1 deletion cannot rescue ICL-induced chromosomal aberrations in
Fancd2-deficient MEFs (Bunting et al., 2012). As all of these studies were
performed in mouse cells, we generated an equivalent human system with
FANCA/53BP1 double deficiency. In agreement with published data, which
suggests that 53BP1 does not play a major role in resistance to IR-induced DSBs,
we did not observe a significant IR sensitivity in 53BP1-depleted FA-A patient cell
lines despite efficient protein depletion (Figure 4.4A) (Chapman et al., 2012;
Iwabuchi et al., 2006; Nakamura et al., 2006; Riballo et al., 2004; Ward et al.,
2004). 53BP1 knockdown did not lead to a suppression of MMC sensitivity in
human FANCA-deficient cells (Figure 4.4B, C). These results provide strong
support for the finding in the mouse system that loss of 53BP1 is not sufficient to
rescue defective ICL repair in FA deficient cells.
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Figure 4.4 Depletion of 53BP1 does not rescue MMC sensitivity in
FANCA-deficient cells.
(A) Survival of RA3087 FANCA-deficient patient cells stably transduced with
shRNA targeting Luciferase (control) or 53BP1 after IR treatment (0-6 Gy).
RA3087 cells transfected with siRNA against ATM were used as positive
control for outcome after IR treatment. Error bars, s.d.. (B) Survival of
RA3087 cells stably transduced with shRNA targeting Luciferase (control)
or 53BP1 or RA3087 cells complemented with FANCA after MMC treatment
(0-100 nM). Error bars, s.d.. (C) Immunoblot showing the expression of
53BP1 in the shRNA transduced RA3087 cells used in A and B.

147

4.5 Partial inactivation of Ku70 or Ku80 does not rescue ICL-induced
proliferation defects in FANCA-deficient cells
We analyzed the possibility of suppressing ICL sensitivity of FANCAdeficient human cells by Ku70 (XRCC6) and Ku80 (XRCC5) inactivation. By
stably expressing three independent shRNA hairpins and their combinations to
target Ku70 or Ku80 in FA-A patient cells, we were able to partially but never
completely deplete Ku70 and Ku80. We found that RA3087 cells with Ku70 or
Ku80 knockdown grew slower than control cells (Figure 4.5A-D). This growth
arrest induced upon Ku70 or Ku80 depletion in consistent with data showing that
Ku70 and Ku80 are essential genes for human but not mouse cells (Fattah et al.,
2008b; Li et al., 2002). Ku70 and Ku80 have been shown to be required for
telomere maintenance and their absence leads to genomic instability and cell
death (Myung et al., 2004; Wang et al., 2009). We used cells with the best Ku70
depletion and did not detect a significant suppression of MMC sensitivity in Ku70depleted RA3087 cells (Figure 4.5E).
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Figure 4.5 Ku70 and Ku80 are essential in human cells and their partial
suppression does not rescue ICL sensitivity in FANCA-deficient cells.
(A) Growth of RA3087 FANCA-/- cells stably transduced with shRNA
targeting Luciferase (control) or Ku70 or complemented with FANCA. Error
bars, s.d.. (B) Immunoblot showing the expression of Ku70 in cells used in
A. (C) Growth of RA3087 cells stably transduced with shRNA targeting
Luciferase (control) or Ku80 or complemented with FANCA. Error bars, s.d..
(D) Immunoblot showing the expression of Ku80 in cells used in C. (E)
Survival of FANCA-/- patient cells stably transduced with shRNA targeting
Luciferase (control) or Ku70 and FANCA-/- patient cells complemented with
FANCA after MMC treatment (0-100 nM). Error bars, s.d..
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4.6 Complete inactivation of NHEJ factors by CRISPR-Cas9 mediated
genome-editing does not rescue MMC proliferation defects in FA cells
To eliminate the possibility that lack of rescue of MMC sensitivity in FApathway-deficient cells was due to the residual NHEJ activity after shRNAmediated knockdown or chemical inhibition, Clustered Regularly Interspaced
Short Palindromic Repeat (CRISPR)-Cas9-dependent gene engineering was
employed to completely inactivate components of NHEJ including DNA-PKcs,
LIG4, and 53BP1 in FANCA-/- patient cells. Successful inactivation of the three
NHEJ factors was verified at the protein level as the expressions of DNA-PKcs,
LIG4, and 53BP1 were not detected in the isolated clones (Brooke Conti, Figure
4.6 A, D, G). Furthermore, as expected, the DNA-PKcs (Clone 1 and 4) and LIG4
(Clone 1, 2, and 3) knockout cells exhibited sensitivity to IR, confirming that
NHEJ was abrogated in these clones (Brooke Conti, Figure 4.6B, E). Similar to
the shRNA-mediated depletion experiment (Figure 4.4A), full removal of 53BP1
by genome editing did not result in significant IR sensitivity (Brooke Conti, Figure
4.6H). Nonetheless, CRISPR-Cas9-mediated complete removal of DNA-PKcs,
LIG4, or 53BP1 did not improve the MMC-induced survival defect in RA3087
cells (Brooke Conti, Figure 4.6C, F, I). These experiments are consistent with the
conclusion that NHEJ suppression does not rescue ICL repair defect in Fanconi
anemia patient cells.
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Figure 4.6 Full inactivation of NHEJ factors by genome-editing does
not rescue MMC sensitivity in FANCA-/- cells.
(A) Immunoblot showing expression of DNA-PKcs in RA3087 FANCA-/cells

and

the

RA3087

FANCA-/-DNA-PKcs-/-

clones

obtained

by

CRISPR/Cas9 gene editing. Sequences at the targeting site of clone 1 and
4 are shown. (B) Survival of wild type fibroblasts (BJ), FANCA-/-, and 2
clones (1 and 4) of FANCA-/-DNA-PKcs-/- cells after IR treatment (0-4 Gy).
Error bars, s.d.. (C) Survival of wild type fibroblasts (BJ), FANCA-/-, and 2
clones (1 and 4) of FANCA-/-DNA-PKcs-/- cells after MMC treatment (0-100
nM). Error bars, s.d.. (D) Immunoblot showing expression of LIG4 in
RA3087 FANCA-/- cells and the RA3087 FANCA-/-LIG4-/- clones.
Sequences around the targeting site of clone 1 and 2 are shown. (E)
Survival of FANCA-/-, FANCA-/- complemented with FANCA, and 3 clones
of FANCA-/-LIG4-/- cells (1, 2, and 3) after IR treatment (0-5 Gy). Error
bars, s.d.. (F) Survival of FANCA-/-, FANCA-/- complemented with FANCA,
and 3 clones of FANCA-/-LIG4-/- cells (1, 2, and 3) after MMC treatment (0100 nM). Error bars, s.d.. (G) Immunoblot showing expression of 53BP1 in
FANCA-/- cells and the FANCA-/-53BP1-/- clones. Sequences around the
targeting site of clone 5 and 6 are shown.

(H) Survival of wild type

fibroblasts (BJ), FANCA-/-, and 2 clones (5 and 6) of FANCA-/-53BP1-/cells after IR treatment (0-4 Gy). FANCA-/-DNA-PKcs-/-.1 CRISPR-targeted
clone from (A-C) was used as IR sensitive-control. Error bars, s.d.. (I)
Survival of wild type fibroblasts (BJ), FANCA-/-, and 2 clones (5 and 6) of
FANCA-/-53BP1-/- cells after MMC treatment (0-100 nM). Error bars, s.d..
All experiments shown in the figure were performed by Brooke Conti, a
fellow student in the lab.
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4.7 Summary of findings and discussion
The observation that NHEJ inhibition could suppress ICL-inducing agent
sensitivity in FA deficient cells has triggered excitement for potential new
therapeutic avenues for FA and novel mechanistic insight into ICL repair.
However, there have been inconsistencies between published studies (Adamo et
al., 2010; Bunting et al., 2012; Chapman et al., 2012; Houghtaling et al., 2005;
Kottemann and Smogorzewska, 2013; Pace et al., 2010). Here we performed an
extensive analysis in cells derived from FA patients to identify whether
inactivating NHEJ factors could rescue ICL-induced proliferation defects. We
found that inactivation of classical NHEJ proteins, including DNA-PKcs, DNA
Ligase IV, and Ku70/80, as well as pathway choice protein 53BP1 or Ligase III
necessary for alternative NHEJ, do not alleviate the ICL sensitivity in FA patient
cells.

Our findings directly contradict published studies including the observation
that DNA-PKcs deficiency could suppress ICL-inducing agent sensitivity in FA
pathway-deficient human cells. The rescue of MMC sensitivity with DNA-PKcs
inhibitor was previously illustrated in HeLa cells with RNAi to deplete FANCA or
FANCD2 (Adamo et al., 2010). However, we failed to rescue MMC sensitivity of
FANCA-/- patient cells by shRNA-mediated depletion of DNA-PKcs or through
chemical inhibitors of DNA-PKcs. It is possible that this inconsistency was a
result of different experimental set-ups. The rescue effect observed in the
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previous studies could be a non-specific effect of the DNA-PKcs inhibitor or
incomplete depletion of the FA transcripts by RNAi treatment. We did not attain
similar observation, despite using the same type and treatment of DNA-PKcs
inhibitor. As evidenced by the pronounced IR sensitivity upon depletion or
chemical inhibition of DNA-PKcs, we are confident that inactivation of DNA-PKcs
does not rescue ICL repair defects in the human FA patient cells. Yet there
remains a possibility that the remnant DNA-PKcs activity from incomplete
depletion or inhibition could still contribute to the MMC sensitivity observed. To
discard that possibility, we characterized the CRISPR/Cas9-generated full
genetic knockout of DNA-PKcs in FA-A patient cells and observed no rescue of
MMC sensitivity (Brooke Conti, Figure 4.6A-C), leading us to conclude that DNAPKcs suppression does not promote ICL resistance in FANCA-deficient human
patient cells. Our findings are consistent with mouse genetic data that showed
that ICL sensitivity of Fancd2 mutant MEFs could not be rescued by DNA-PKcs
deficiency (Houghtaling et al., 2005).

Divergent relationship between NHEJ and ICL repair among experimental
systems appears to be a common theme. This is well illustrated by the
contradictory effects of LIG4 suppression on ICL-induced drug resistance in C.
elegans and chicken DT-40 cells, reflecting potential differential regulations of
DSB repair pathway choice and the FA pathway in different organisms (Adamo et
al., 2010; Pace et al., 2010). Our analysis provides the first genetic evidence
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against a rescue of crosslink repair defects by LIG4 inactivation in human cells.
Ablation of LIG4 did not promote ICL resistance in FANCA-depleted HCT116
cells. It should be noted that the HCT116 cells lack functional MLH1 and MSH3
proteins, whose role in ICL repair remains incompletely understood. We thus
tested the effect of CRISPR-mediated LIG4 inactivation directly in FANCA-/patient cell lines and observed no evidence for a rescue of ICL sensitivity (by
Brooke Conti, Figure 4.6D-F).

In this study, we showed that 53BP1 inactivation did not restore ICL repair
proficiency in FANCA-deficient cells, in agreement with the previous study in the
mouse (Bunting et al., 2012). This observation indicates that a potential increase
in DSB end resection with 53BP1 deficiency, which disfavors NHEJ could not
compensate for the lack of FANCA-dependent ICL repair (Bunting et al., 2012;
Knipscheer et al., 2009; Raschle et al., 2008).

The analysis of rescue of FA cellular phenotypes by Ku70/Ku80
inactivation in human cells is challenging, as Ku70 and Ku80 function is essential
at human telomeres (Fattah et al., 2008a; Li et al., 2002). Depletion of Ku80 was
nonetheless shown previously to partially rescue ICL sensitivity in FA-C and FAD2 patient cells (Adamo et al., 2010; Pace et al., 2010). In mouse cells, Ku80 is
not essential and its knockout leads not only to lack of rescue, but to an increase
in sensitivity to ICL-inducing agents when combined with Fancd2 deficiency
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(Bunting et al., 2012). Here, we did not observe a rescue of ICL sensitivity in
FANCA-deficient cells when Ku70 or Ku80 were partially depleted. Until Ku70 or
Ku80 mutants that retain the telomere protection function but lose specifically the
NHEJ activity are identified, we will not know for sure if full inhibition of the KU
complex would lead to rescue of FA phenotypes.

It should be noted that in most of our experiments, we focused our
attention on the effect of NHEJ suppression on the proliferation of FA-patient
cells under ICL treatment without additional analysis on the state of crosslinkinginduced chromosomal abnormality, which is a diagnostic feature of FA cells.
NHEJ is thought to contribute to the chromosomal translocation and the
formation of radial chromosomes. Therefore, there is a possibility that NHEJ
inactivation could rescue the radial chromosomes phenotype or could change the
types of chromosomal aberrations without rescuing the proliferation defect in ICLtreated FA-patient cells. There is in fact some recent evidence in support of such
phenomenon that chromosomal translocation/radial chromosomes may not be
the direct cause of cellular sensitivity to crosslinks or defective DSB repair
(Bunting et al., 2010). This merits further investigation in the future.

It should also be noted that our genetic experiments were mostly
undertaken in FANCA-/- fibroblasts because as a member of the core complex its
abrogation leads to a full inactivation of FA pathway. We also took into
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consideration that majority of FA patients carry FANCA mutations. While it is
possible that other members of the FA pathway may have unique relationships
with NHEJ, we showed that DNA-PKs inhibitors did not rescue the ICL sensitivity
of human patient cells lacking FANCD2 or SLX4, the downstream components of
the FA pathway. Aberrant NHEJ activity is thereby unlikely to be responsible for
the ICL-inducing agent sensitivity of FA-deficient cells. In addition, our study was
performed on human patient fibroblasts rather than hematopoietic stem cells
(HSCs), which may be more relevant to FA-associated bone marrow failure. A
recent report proposes a correlation between the effect of NHEJ down-regulation
and a rescue of HSCs defects in FA-deficient mouse and human models via an
inhibition of TGF-β signaling (Zhang et al., 2016). Whether direct NHEJ
suppression would produce a similar rescue effect on FA-deficient HSCs needs
to be explored.

Together our findings have significant implications for the care of FA
patients. With our current results, we conclude that inhibition of NHEJ would not
be able to suppress cellular sensitivity to crosslinking agents in FA-patient cells
and hence it would not be a viable treatment option for FA patients. It is still
important to continue to identify and understand the pathways that may crosstalk
with FA pathway and which could be involved in the aberrant processes in FAdeficient cells so that the relevant targeted therapy could be developed in the
future.
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Chapter 5: Discussion
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5.1 The role of FAN1 in DNA interstrand crosslink repair
In this study, we analyzed FAN1 function in human and mouse cells. Cell
lines derived from KIN patients and Fan1-deficient mouse embryos, provide a
powerful genetic tool to study the molecular mechanisms of FAN1 function in
DNA interstrand crosslink (ICL) repair. Our work demonstrates that FAN1 is
necessary for cellular resistance to DNA ICL-inducing agents as FAN1-deficient
cells display decreased proliferation and aberrant chromosomal structures after
treatment with them. Our study also highlights that the ICL repair function of
FAN1 is independent of the FA pathway and is not contingent upon interaction
with the ID2 complex. This finding provides a plausible explanation for the
phenotypic differences observed between FA and KIN patients.

5.1.1 The mechanism of FAN1 in ICL repair
Our study demonstrates that the sensitivity of cells derived from KIN
patients to ICL-inducing agents can be complemented by ectopic expression of
wild-type FAN1. Further analysis revealed that KIN patient cells have intact DNA
damage G1/S and G2/M checkpoints, as well as robust FANCD2 ubiquitination
especially following ICL treatment. These results suggest that FAN1 might
function downstream of DNA damage response and FA pathway activation. To
further characterize the mechanism of FAN1 in ICL repair, we generated Fan1deficient mouse embryonic fibroblasts. The study showed that Fan1-knockout
mouse cells recapitulate the behavior of human cells deficient for FAN1. Namely,
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the nuclease activity of FAN1 proved necessary for protection against various
ICL inducing agents - MMC, acetaldehyde and formaldehyde, but not to noncrosslink replication stress inducers such as hydroxyurea or camptothecin. Our
analysis also suggests that FAN1 is not haploinsufficient for ICL repair as MEFs
heterozygous for the Fan1-deficient allele were resistant to the same drug
treatments. These findings are consistent with karyomegalic interstitial nephritis
(KIN) being a recessive disease in humans (Zhou et al., 2012).

The UBZ domain-mediated interaction between FAN1 and the ID2
complex is believed to be crucial for the recruitment of FAN1 to the sites of
crosslinked DNA and its involvement in ICL repair (Kratz et al., 2010; Liu et al.,
2010; MacKay et al., 2010; Smogorzewska et al., 2010). However, our data
indicate that FAN1 can facilitate ICL repair independently of the UBZ domain.
Our work in collaboration with the Seidman lab demonstrates that the UBZ
domain is not necessary for the localization of FAN1 to the site of crosslinks
(Thongthip et al., 2016). The recruitment of FAN1 relies primarily on the SAP
domain, with the UBZ domain playing an auxiliary role in the additional
enrichment of FAN1 at the site of damage. Based on the structural analysis of
FAN1, the direct interaction of the SAP domain with crosslinked DNA provides
proper structural remodeling of the DNA substrate, which is required for
appropriate incision by the nuclease domain of FAN1 and subsequent ICL repair
(Gwon et al., 2014; Wang et al., 2014; Zhao et al., 2014). Consistent with the
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SAP domain being important for recruitment to the ICL, we found that ectopic
expression of FAN1 with mutations in its SAP domain failed to rescue ICL repair
defect in Fan1-deficient mouse cells. The observation that the SAP domain is
sufficient for the efficient recruitment of FAN1 to the damage site raises the
possibility that FAN1 could function in cellular contexts where the FA proteins are
unable to act efficiently; for example, in the G0 or G1 stage of the cell cycle or at
a subset of DNA lesions that have structures other than convergent replication
forks.

The fact that the UBZ of FAN1 is not necessary for resistance to ICL
inducing agents, prompts a question of the significance and function of the UBZ
domain and the FAN1- FANCD2 interaction. It is possible that the UBZ domain is
required for the functions of FAN1 and the ubiquitinated FANCD2/FANCI that are
unrelated to the repair of ICLs. The UBZ domain is a more recent evolutionary
extension of FAN1 protein architecture (MacKay et al., 2010; Smogorzewska et
al., 2010). In yeast, Fan1 is capable of conferring ICL repair activity in the
absence of the UBZ domain (Fontebasso et al., 2013). Study from John Rouse
laboratory showed that the UBZ domain of FAN1 is essential for processing
replication forks and for protection against chromosomal instability after
treatment with HU and MMC (Lachaud et al., 2016a). Our experimental
conditions however, did not reveal a similar requirement for UBZ domain in
maintenance of chromosomal stability after MMC treatment. One potential
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difference is that we are working with a knockout model of FAN1 and the Rouse
lab works with a nuclease dead allele of FAN1. Nevertheless, it remains to be
determined whether defects in the fork-protective function of FAN1 could
contribute to KIN development. Another possibility that remains to be explored is
the role of the UBZ domain in the potential functions of FAN1 in regulation of
DNA mismatch repair (MMR) and nucleotide repeat expansion pathways, which
are associated with diseases like hereditary colorectal cancer (CRC) and
Huntington’s disease (HD) (Bettencourt et al., 2016; Segui et al., 2015) (see
section 5.2.3).

Consistent with the UBZ domain not being necessary for ICL resistance,
we showed that FAN1 has ICL repair functions outside of the FA pathway. Our
data are consistent with studies in DT40 chicken cells, which report that FAN1 is
not epistatic with FANCC and FANCJ in ICL resistance (Yoshikiyo et al., 2010).
Based on the MMC-induced proliferation defect, the FA protein network
represents the predominant ICL repair pathway in mammalian cells (Lachaud et
al., 2016b; Thongthip et al., 2016; Zhou et al., 2012). However, we found that
FAN1 depletion/inactivation can further enhance the ICL-induced sensitivity of
FANCD2-depleted BJ cells, SLX4-depleted BJ cells, and FANCA-patient cells.
Similarly, we observed that FAN1 depletion could also exacerbate chromosomal
aberrations in MEF cells lacking FANCD2 upon exposure to a high level of ICLs.
These results firmly establish the presence of an FA pathway-independent
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functions of FAN1 that can protect cells from accruing extensive genomic
alterations upon exposure to ICL agents.

5.1.2 Genetic interaction between FAN1 and other nucleases in ICL repair
In vitro biochemical analyses of SLX4/FANCP and XPF/FANCQdependent processing of the crosslinks and the ICL unhooking studies from
Xenopus egg extracts, strongly support the major involvement of the 3’ flap
endonuclease activity of XPF/FANCQ, but not FAN1, in performing ICL
unhooking (Douwel et al., 2014; Hodskinson et al., 2014). Lack of SLX4interacting XPF sensitizes human cells to ICL-inducing agents to a greater extent
than the depletion of FAN1. However, it is evident from the published
biochemical analyses as well as from our own unpublished data, that FAN1 is
very effective in incising and unhooking different types of crosslink substrates in
vitro through its endonuclease and exonuclease activities (Pizzolato et al., 2015;
Zhao et al., 2014)(A. Wang, L. Timashev, and A. Smogorzewska, unpublished).
This suggests that the true function of FAN1 has not yet been identified. FAN1
may be involved in repair at stalled forks, which do not look like the converging
replication forks formed on plasmids in the Xenopus egg extracts. It is also
possible that FAN1 predominantly works in G1 unlike typical FA-associated
proteins that function in S phase as illustrated by the experiments in Xenopus
(Raschle et al., 2008). Another explanation for the lack of a discernible ICL
unhooking defect in egg extracts depleted of FAN1, could be the presence of
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redundant nucleases in the extracts. In our study, we identified SNM1A as being
redundant with FAN1 during the ICL damage response. Unlike FAN1, SNM1A
deficiency alone exhibits very mild crosslink sensitivity in mammalian cells
(Ahkter et al., 2005; Dronkert et al., 2000). In fact, our analysis demonstrated that
depletion of SNM1A in fibroblasts did not elicit any significant sensitization to
ICLs. On the other hand, cells lacking both FAN1 and SNM1A became as
sensitive to crosslinking agents as cells lacking the FA proteins such as SLX4 or
FANCD2. This result suggests that the ICL repair could be severely
compromised when both SNM1A and FAN1 are absent. The analysis of ICL
incision and repair after co-depletion of FAN1 and SNM1A in the Xenopus egg
extracts could shed further light on the unhooking of the ICLs. The long-term in
vivo effects of a combined SNM1A and FAN1 deficiency have not been studied.
It is possible that the redundant functions of the two nucleases contribute to the
protection of kidney and liver tissues. It will be interesting to determine if the
Snm1a knockout animals develop KIN and whether combined inactivation of
Fan1 and Snm1a could exacerbate KIN phenotypes.

5.2 The role of FAN1 in the protection of tissue function and human disease
The Fan1 knockout mouse model exhibits karyomegaly in the kidney and
liver. This phenomenon demonstrates age-dependence, as stronger phenotypes
become more apparent in the older mice. Moreover, even though the Fan1deficient mice display normal hematopoiesis under unstressed conditions, they
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develop acute bone marrow dysfunction when challenged with MMC, which
severely affects animal survival. Overall, our mouse model recapitulates the
pathology of human KIN in which FAN1 mutations have been identified (Zhou et
al., 2012). Although FAN1 mutations in the general population are rare, patients
with such mutations are predicted to have an adverse reaction if they were
treated ICL-inducing chemotherapeutics.

5.2.1 The role of FAN1 in the suppression of KIN pathogenesis
FAN1 protein appears to be ubiquitously expressed in various human
tissues with a significant level detected in the kidney and liver, two of the tissues
affected in KIN patients. Fan1-deficient mice display karyomegaly in epithelial
cells lining the renal tubules in the kidney as well as in the hepatocytes in the
liver, as early as at six months of age. Moreover, the number as well as the
average area of the enlarged nuclei increases with time, suggesting that this
phenomenon is a continuous and chronic process. The FISH analysis of 18month-old mice revealed increased ploidy at three independent genomic loci
consistent with reduplication of the genome in the karyomegalic nuclei. This
observation implies that affected cells undergo replication cycles, which are not
followed by successful mitoses. It is unclear at this point if the whole genome, or
only parts of the genome are reduplicated in the absence of FAN1. In KIN
patients, the karyomegalic nuclei in kidney tissue have also been to shown to
contain polyploid DNA. This supports our finding in Fan1-deficient mice, that the
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enlargement of nuclei is a result of polyploidization that takes place in the
absence of FAN1 (Bhandari et al., 2002; Spoendlin et al., 1995).

One possible reason for endoreduplication is exit from prolonged cell cycle
arrest in the setting of persistent DNA damage. The arrest may not last
permanently and is eventually overcome by mitosis and/or cytokinesis bypass
with a new round of replication licensing and initiation cycle (Davoli et al., 2010).
Alternatively, the absence of FAN1 may directly interfere with chromosome
segregation or cytokinesis preventing the division of the duplicated genomes and
cells, leading to an increase in ploidy level. More work is needed to understand
the polyploidization of different tissues affected in KIN patients. The question of
how polyploidization is allowed to take place in Fan1-deficient animals despite
the presence of p53 also merits further investigation. The extensive karyomegaly
seen in the liver in this mouse model could be useful for understanding the
mechanism of polyploidization in normal hepatic tissue during aging.

Analysis of 18 months old Fan1-deficient mice revealed that, similar to KIN
patients, the mice exhibit liver function abnormality as determined by an increase
in AST and ALT and a reduction in the level of serum albumin and globulin,
which are synthesized in the liver.

Hepatocytes are especially prone to

increasing their ploidy during development and in response to insults including
DNA damage (reviewed in (Gentric and Desdouets, 2014). The proportion of
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karyomegalic polyploid hepatocytes is significantly higher in livers of Fan1deficient mice compared to that of wild-type animals at 18 months. Based on our
observation that the polyploidization is a progressive event and that there is a
strong correlation between ploidy increase and functional decline of the animals,
it is highly likely that polyploidization is a pathogenic and not an adaptive event in
Fan1-deficient animals.

Although both the liver and the kidney of the Fan1-deficient mice display
karyomegaly at 18 months, we only observe liver but not kidney dysfunction. The
serum level of urea nitrogen, creatinine and electrolytes that we measured are
more representative of glomerular function and are not specialized markers of
proximal tubule function, the primary subtype of kidney tissues affected in Fan1deficient mice (Hall et al., 2014; Labarga et al., 2009; Norden et al., 2000). Other
markers that more accurately correspond with changes in proximal tubule
function such as the urine level of glucose, amino acids and tubular proteins (e.g.
retinol-binding protein) might be more appropriate for future assessment of
functional impairment (Hall et al., 2014).

The kidney is a very resilient organ with high buffering capacity of tissue
function and usually its functional decline only becomes apparent upon loss of
the majority of kidney tissue. Our study was done in mice with C57BL/6J genetic
background, and this strain is known to be less susceptible to developing kidney
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deficiency. Another factor is a relatively short lifespan of mice which might not
have allowed for sufficient kidney impairment despite the absence of FAN1.
Additional insults including nephrectomy of one kidney or increase in the
endogenous DNA damage load (see section 5.3), may be necessary to see
effects of FAN1 deficiency on kidney function. Alternately, the genetic differences
between mice and humans might be responsible for the less severe phenotypes
exhibited by Fan1-deficient mice. It is possible that additional gene inactivation of
a redundant nuclease such as SNM1A might expose kidney dysfunction in mice.

5.2.2 The role of FAN1 in the protection of bone marrow stem cells
In contrast to patients with Fanconi anemia, KIN patients do not develop
pancytopenia at a young age (Zhou et al., 2012). However, when diagnosed with
kidney failure, some KIN patients exhibit mild anemia of a presently unknown
origin (Godin et al., 1996). The anemic phenotype observed in KIN patients could
be an outcome of prolonged kidney dysfunction or alternatively a direct
consequence of bone marrow abnormalities, prompting us to evaluate the bone
marrow function of Fan1-/- mice. These mice at either young or old age, display
normal levels of peripheral blood cells compared to wild-type animals. The
analysis of bone marrow histology and quantification of hematopoietic stem cell
(HSC) frequency in 3 and 18 months old Fan1-/- mice do not reveal a discernible
change from the wild type levels. In competitive reconstitution experiments, LTHSCs derived from bone marrow of Fan1-/- mice were able to engraft with the
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same efficiency as their wild-type counterparts. This result suggests that the
function of hematopoietic stem cells is not compromised in Fan1-deficient mice.
Additionally, we also determined that Fan1 deficiency does not significantly
enhance the HSC defect observed in Fancd2-/- animals. Taken together, these
data imply that the activity of FAN1 is dispensable for the protection of
hematopoietic stem cells from DNA damage under unperturbed conditions.

Only one Fan1-/- mouse in our study cohort exhibited signs of blood
cytopenia during the first 18 months of life, which is most likely a sporadic event.
Despite not being required under unstressed conditions, FAN1 is essential for the
maintenance of hematopoiesis when animals are challenged with doses of
crosslinking agents that can be well tolerated by the wild type animals. We
determined that the bone marrow and thymus were particularly prone to ICLinduced toxicity in Fan1-deficient animals and that injection of these animals with
MMC resulted in 90% mortality. Moreover, analysis of the c-Kit+ cells, which
represent the hematopoietic stem cell population, revealed that the frequency of
these cells, including the LSK and the LK populations is severely affected by the
treatment with MMC. This result indicates that FAN1 is indispensable for the
protection of both the stem and progenitor cells in the bone marrow upon
exposure to an ICL-challenge. The sensitivity of the HSCs was specific to the
ICL-induced damage, as ionizing radiation did not elicit the same level of
pathology. Defects in the kidney and liver were not detected under the acute
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MMC treatment used in this study. More chronic, low dose treatments might be
necessary to induce kidney and liver dysfunction in young Fan1-/- animals.

5.2.3 FAN1 and other human diseases
Other than KIN, mutations in FAN1 have been implicated as a pathogenic
factor in a number of diseases including polyglutamine diseases such as
Huntington’s disease (HD) and multiple spinocerebellar ataxias (SCAs),
hereditary colorectal cancer (CRC) and high-risk pancreatic cancer (PC)
(Bettencourt et al., 2016; Segui et al., 2015; Smith et al., 2015). Occurrences of
pulmonary carcinoma and hepatic lymphoma have also been reported in Fan1
knockout mice at 20 months of age (Lachaud et al., 2016a). Additionally, a
deletion of 15q13.2-13.3 which includes FAN1 and 4 other genes, has been
identified in patients with Schizophrenia (SZ) (Chen et al., 2016; Forsingdal et al.,
2016).

It is unclear how FAN1 variants are involved in the pathogenesis of these
diseases. In the case of hereditary CRC, mutations associated are either
truncation mutations such as p.Cys47* and p.Arg952* or missense mutations
including p.Asp140Thr, p.Pro340Ser, and p.Arg591Trp. FAN1+/- heterozygous
cells with p.Cys47* variant were reported to have almost wild-type level of ICL
resistance whereas among all the missense mutations, the p.Asp140Thr FAN1
variant was the only one to display ICL-repair defects as shown by its failure to
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complement the ICL sensitivity of FAN1-deficient 293T cells (Segui et al., 2015).
The ICL repair efficiency of cells carrying the pancreatic cancer variant
p.Met50Arg of FAN1 has yet to be assessed (Smith et al., 2015). Nonetheless,
this is the first time that the UBZ domain of FAN1 has been implicated to be
functionally significant in human studies. To date, there is no evidence indicating
the loss of heterozygosity or reduced level of FAN1 expression in CRC or PC
tumor samples that harbor FAN1 variants (Broderick et al., 2017; Segui et al.,
2015; Smith et al., 2015). These observations suggest a possibility that the FAN1
variants act as dominant alleles. Alternatively, the mutations could potentially
affect the function of FAN1 outside of ICL repair, which may be affected by a
haploinsufficiency of FAN1.

DNA mismatch repair (MMR) is one of the likely cellular processes that
may require the activity of FAN1 for the protection against CRC and Huntington’s
disease (Bettencourt et al., 2016; Segui et al., 2015). The function of FAN1 in
MMR has not been formally demonstrated, however, FAN1 was shown by
multiple labs to be able to interact with MMR components including MLH1, MLH3,
PMS2 and PMS1 (Kratz et al., 2010; Liu et al., 2010; MacKay et al., 2010;
Smogorzewska et al., 2010). In accordance with this idea, mutations in MMR
factors have been implicated in the control of DNA repeat stability that is known
to underlie CRC and polyglutamine disease predisposition syndromes (Iyer et al.,
2015; Mirkin, 2007; Tome et al., 2013; Wheeler et al., 2003). Given that the type
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of CRC described in patients with FAN1 variants is MMR proficient, FAN1 might
not be directly involved in the main MMR pathway (Segui et al., 2015). However,
its function might be important for the modulation of the pathway to ensure that
faithful DNA replication and repair occur, especially within the repetitive regions
of the genome. In order to verify the plausible function of FAN1 in MMR and in
the protection against repeat-instability disorders, more data need to be collected
with larger control populations and the hypothesized functions of FAN1 need to
be tested in cellular and animal models.

5.3 The endogenous source of ICL damage that requires FAN1’s repair
activity
The major unanswered question in the pathophysiology of KIN is the
nature of lesions that FAN1 repairs. Given the recent data implicating
acetaldehyde and formaldehyde in the pathogenesis of Fanconi anemia
(Garaycoechea et al., 2012; Hira et al., 2013; Langevin et al., 2011; Pontel et al.,
2015), aldehydes are attractive candidates as endogenous sources of damage
that could promote KIN in the absence of FAN1. Based on the sensitivity of
Fan1-deficient MEFs to aldehydes, there was a possibility that FAN1 was
involved in the repair of acetaldehyde- or formaldehyde- induced damage,
particularly in the kidney and liver that are affected in KIN patients.
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Our data indicate a mild growth defect in Fan1-/-Adh5-/- double-deficient
animals, which implies that an increased basal formaldehyde level in Adh5deficient mice could lead to the accumulation of formaldehyde-induced DNA
damage that affects growth. The absence of ADH5 also results in smaller
number of pups produced per litter, a phenotype which is slightly worsened upon
inactivation of FAN1. Given that the testis and ovary from Fan1-/-Adh5-/- animals
are within normal limits histologically (data not shown), we hypothesize that
FAN1 might be required to maintain normal embryonic development, protecting
developing embryos from formaldehyde insults, which arise in the absence of
ADH5.

Kidney and liver function in Fan1 mutant animals with Aldh2 or Adh5
inactivation are no different than in the wild-type or other single mutant control
mice. The histology of kidney and liver from 3-month-old Fan1-/-Aldh2-/- or Fan1/-Adh5-/- animals is within normal limits with no significant presence of
karyomegalic cells. This result suggests that KIN phenotypes cannot be
accelerated by ablating either acetaldehyde or formaldehyde detoxification in
Fan1-deficient animals. Moreover, we can attribute the karyomegaly phenotype
primarily to the absence of FAN1. At 12 months of age, Fan1 single or the DKO
mice lacking both Fan1 and Aldh2 or Adh5 mice displayed similar levels of renal
karyomegaly. Also, there was no sign of enhanced proliferation or DNA damage
in the kidney tissue of Fan1-/-Aldh2-/- or Fan1-/-Adh5-/- animals. The fact that
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suppression of Aldh2 or Adh5 in Fan1-deficient mice did not promote tissue
karyomegaly and tissue damage, challenges the idea that acetaldehyde and
formaldehyde contribute to KIN pathogenesis. Furthermore, even when Fan1-/Aldh2-/- animals were additionally stressed with increased levels of acetaldehyde
due to ethanol feeding in the absence of the detoxification pathway, no renal
karyomegaly or kidney/liver functional decline was observed. The stressenhancing experiment with Fan1/Adh5 series is still on-going.

Lack of synergy between Fan1 and Adh5 in promoting kidney disease was
unexpected. Recent work demonstrated that inactivation of ADH5, which is
responsible for formaldehyde detoxification, resulted in tissue karyomegaly,
kidney failure, and abnormal liver function when combined with Fancd2
deficiency (Pontel et al., 2015). It is possible that the synergy was not seen
because the etiology of karyomegaly in the absence of FANCD2 is different from
its etiology in the absence of FAN1. Fancd2-/-Adh5-/- mice develop glomerular
damage before they develop karyomegaly and this damage is absent in KIN
patients and Fan1-deficient mice. Future experiments will be required to identify
the mechanism of karyomegaly in both genetic backgrounds.

Besides effects on growth, ADH5 deficiency also had an adverse effect on
the maintenance of the hematopoietic stem and progenitor populations in young
3 months old Fan1-/-Adh5-/-. This effect was not seen in Fancd2-/-Aldh2-/- mice.
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The stronger phenotypes observed in Fan1-/- mice lacking ADH5 when
compared to mice lacking ALDH2, are reminiscent of the effects of these two
aldehyde detoxification deficiencies in Fanconi anemia mice with Fancd2-/-Adh5/- mice exhibiting more severe defects compared with Fancd2-/-Aldh2-/-. This
could stem from the more severe nature of formaldehyde induced lesions or
alternatively due to the increased number of lesions when ADH5 was absent.

Despite a reduction in the LSK frequency, the remaining Fan1-/-Adh5-/HSCs can effectively function to support sufficient production of peripheral blood
cells. We further assessed HSC function by testing the ability of the long-term
HSCs to reconstitute hematopoiesis after serial transplantation. While there is no
discernible functional compromise in the engraftment efficiency of the bone
marrow lacking FAN1 in combination with ADH5 or ALDH2 after the first
transplant, the secondary transplant revealed that both FAN1 and ALDH2 are
required for long-term reconstitution of blood cells. Secondary transplant studies
are still ongoing with Fan1-/-Adh5-/- mice.

Taken together, our results show that FAN1 contributes very subtly, to the
protection of the bone marrow against acetaldehyde and formaldehyde-induced
damage in the bone marrow. It is possible that in the bone marrow, nucleases
associated with the Fanconi anemia pathway such as XPF are more active at
clearing out aldehyde-induced crosslinks. Furthermore, SNM1A, a redundant
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nuclease may be able to efficiently compensate for the lack of FAN1 in the bone
marrow, masking the contribution of FAN1 to the repair of aldehyde-induced
crosslinks. The generation and characterization of Fan1-/-Snm1a-/-Aldh2-/- and
Fan1-/-Snm1a-/-Adh5-/- triple mutant mice would be of interest to examine such
hypothesis.

Several

questions

regarding

the

contributions

of

FAN1

to

KIN

pathophysiology remain unanswered. We still do not know the endogenous
source of lesions that leads to KIN pathogenesis. Based on our studies, it is
unlikely that these are acetaldehyde or formaldehyde. It is still possible that
FAN1 is required for the repair of damage inflicted by other reactive aldehydes.
Therefore, investigating the contributions of other members of the aldehyde
dehydrogenase/alcohol dehydrogenase family might of value. In addition, other
metabolites that cause ICLs are possible candidates. To address this possibility,
performing an unbiased screen for metabolic genes whose inactivation in
combination with FAN1 deficiency produces a synthetic lethality or a synthetically
reduced fitness at the cellular level and an acceleration of KIN phenotypes at the
whole organism level, may prove to be a fruitful approach. Furthermore, the
possibility of KIN being driven by lesions other than ICLs should not be
overlooked. For instance, ischemia reperfusion model, which induces significant
oxidative damage, could be used to stress the kidney to examine its impact on
the maintenance of renal tubular cells and kidney function in the presence and
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absence of FAN1. Identification of the endogenous lesion that needs FAN1 for
its removal will be important not only for the basic understanding of FAN1
function but may also lead to therapeutic strategies to protect liver and kidney
function in more general population.
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Chapter 6: Materials and Methods
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6.1 General procedures
6.1.1 Mammalian cell culture
Human patient fibroblasts were transformed by HPV16 E6E7 and
immortalized by expression of catalytic subunit of human telomerase (hTERT).
Cells were cultured at 3% oxygen and maintained in DMEM containing 15% FBS,
100 U/mL penicillin, 0.1 μg/mL streptomycin, 0.1 mM nonessential amino acids,
and 0.1 mM glutamax (Life Technologies).

Primary MEFs were isolated from E13.5 embryos using standard
techniques and cultured at 3% oxygen and in DMEM containing 15% FBS, 100
U/mL penicillin, 0.1 μg/mL streptomycin, 0.1 mM non-essential amino acids and
glutamax (Life Technologies). MEFs were immortalized at passage 2 using
pMSCVNeo HPV16E6E7.

6.1.2 Viral transduction of mammalian cells
For viral infections, 293T cells plated in 10 cm dishes the day before were
transfected with 6 μg of plasmid DNA and the viral packaging vectors using
TransIT reagent (Mirus). The media was changed once, 24 hours after
transfection. The virus-containing supernatants were harvested at 24 hours and
48 hours later and filtered (0.45 μM filter). Polybrene was added at a final
concentration of 4 μg/mL before used to infect the targeted cells. Cells were
infected 2-3 at 12 hours intervals for each experimental condition. 24 hours after
the infection, the infected cells were put under selection with the appropriate
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antibiotic (puromycin (2 μg/mL), blasticidin (500 μg/mL), hygromycin (100 μg/mL)
or neomycin (600 μg/mL). Selection was deemed completed after all uninfected
control cells had died in the present of antibiotic.

6.1.3 DNA damage sensitivity assays
Analyses of cell survival under DNA damaging agent treatment were
performed in a 6-well plate format (except the experiments from Figure 4.2B-E,
Figure 4.4A-B, and Figure 4.5E that were performed in a 96-well plate format) as
previously described (Kim et al., 2013). Cells were seeded in triplicate at a
density of 3.5-4 × 104 per well in a 6-well plate or 500 cells per well in a 96-well
plate (Opaque White MicrotestTM plate (BD, 353296)) before treatment with
DNA damaging drugs (MMC (0-75 nM), HU (0-100 nM), CPT (0-20 nM)) 24
hours later. For cell survival assay following ionizing radiation, cells were first
irradiated in suspension before plating. In the case of NU7026 or NU7441 pretreatment for inhibition of DNA-PKcs, cells were first pre-treated with 10 μM
NU7026 or 1 μM NU7441 for 3 hours before being subjected to MMC treatment
in a media containing the corresponding DNA-PKcs inhibitor for the duration of
the survival assay.

In the 6-well plate format, the cells were split once after 3 days of drug
treatment. After additional 3–4 days of further culturing, cell numbers were
determined using the Z2 Coulter Counter (Beckman Coulter). For the 96-well
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plate format, cell viability was determined after 5 days in culture using the
CellTiter-Glo reagent (Promega). 500 cells were plated per well in a 96-well
plate (Opaque White MicrotestTM plate (BD, 353296) and allowed to grow
following the DNA damaging agent treatment for 4-5 days until the most
confluent well reached ~ 80-90% confluency. 50 μl CellTiter-Glo reagent were
added to each well, which contained 100 μl of media, mixed well by repeated
pipetting and allowed to incubate at room temperature for 15 minutes before the
luminescence signals were read.

Luminescence signal/cell viability post-

treatment were normalized to Luminescence signal /cell viability of the untreated
samples to give the percentage of survival.

6.1.4 Cell proliferation assays
Cell proliferation was determined using the 96-well plate format. 500 cells
were plated per well in a 96-well plate (Opaque White MicrotestTM plate (BD,
353296)). Cell viability as determined by the luminescence signal was measured
daily for 6 days using the CellTiter-Glo reagent (Promega). The luminescence
signals were normalized to the luminescence signals measured on day 1 to give
the percentage of cell proliferation.

6.1.5 siRNA-mediated knockdown
For siRNA transfection, cells were subjected to reverse transfection, using
RNAiMax (Thermo Fisher). siRNAs were prepared at a final concentration of 25
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nM in 500 μl of Opti-MEM medium (Gibco) before mixing with 5 μl of
Lipofectamine RNAimax (Thermo) and transferred to empty 6-well plate. After 20
minutes of incubation at RT, ~ 150,000 cells diluted in 2 mL of media with no
added antibiotic were added on top of the RNAi complexes per well. The media
was changed once 24 hours later, and the RNAi-transfected cells were used at
72 hours following the transfection for each experiment.

6.1.6 shRNA-mediated knockdown
DNA-PKcs, 53BP1, Ku70 and Ku80 shRNA targeting sequences were
amplified from ssDNA template using miRXhoF (cagaaggctcgagaaggtatattgctgttgacagtgagcg) and miREcoRIR (ctaaagtagccccttgaattccgaggcagtagca)
primers. The original shRNA expression vector pAHM - (pALPS-Hygro-miR30)
vector was mutagenized to remove the EcoRI site within the hygromycin gene to
leave only a unique EcoRI cut site within the miR30 cassette of the vector. The
XhoI/EcoRI-digested amplified products were then ligated to the XhoI/EcoRI
digested pAHM vector. FANCA was stably knocked down using pAHM-UltramiR
generated by inserting MluI-HpaI fragments of shFANCA pGipz-UltramiR
(Transomics) into pAHM. Sequences of shRNAs are given in 6.2.4. Cells were
transduced with shRNA-expressing lentiviruses and selected for 1 week with 200
μg/mL hygromycin until the selection was deemed completed after all uninfected
control cells had died in the present of antibiotic.
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6.1.7 Gene targeting
RA3087 FANCA-/- human fibroblasts and Fan1-/- MEFs were transduced
with lentivirus expressing of pCW-Cas9 vector encoding dox-inducible Cas9
expression cassette (Wang et al. 2014b) (plasmid 50661, Addgene, originally
from Lander and Sabatini labs, MIT). After selection with 50 μg/mL hygromycin
(for MEFs) or 3 μg/mL puromycin (for human fibroblasts), a single clone with
undetected basal level of pCW-Cas9 but showed increased in expression
following dox-induction was selected before being transduced with lentivirus
expressing single guide RNA (sgRNA) (Sanjana et al. 2014; Wang et al. 2015)
targeting FAN1 in FANCA-/- human fibroblasts or Snm1a in the Fan1-/- MEFs.
Following selection in 3 μg/mL puromycin (for MEFs) or 5 μg/mL blasticidin (for
human fibroblasts), cells were treated with 100 ng/mL doxycyclin for 48 hours
before single cells were plated in 96-well plates. Isolated clones were screened
for CRISPR-mediated genome editing at target region by sequencing of genomic
DNA. The reduction of the corresponding mRNA transcripts determined by RTPCR or protein level was used to validate knockout. Sequences of sgRNAs are
listed in 6.2.5.

6.1.8 G1/S and G2/M Checkpoint analysis
G1/S checkpoint
Cells were treated with 10 Gy IR. After resting for 10 hours, cells were
pulsed by 10 µM BrdU for 30 minutes. The cells were then trypsinized and
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harvested for fixation and analysis. Cells were fixed in ice-cold 100% methanol
slowly while vortexing. After fixation, the fixed cells were stored at -20 oC at least
24 hours before staining. Methanol were then replaced by 1 mL 2 N HCl plus 0.2
mg/mL of pepsin and cells were incubated for 30 minutes at room temperature.
To neutralized HCL, 3 mL of 0.1 M sodium tetraborate (pH 8.5) were added.
Cells were then washed once in PBS before a second washed with 1%BSA/0.5%
Tween-20/PBS. The staining was done with 1:20 FITC-conjugated anti-BrdU
antibody (BD) in 1%BSA/0.5% Tween-20/PBS at room temperature for 30
minutes in the dark. Cells were washed once with PBS before resuspended in
500 µl of PBS/PI (20µg/mL)/RNase (200µg/mL) solution, incubated for 15-20
minutes at 37 oC and analyzed by LSRII flow cytometer (BD Pharmingen).

G2/M checkpoint
Cells were treated with 10 Gy IR and rested for 1 hour before arrested
with 100 ng/µl nocodazole for 18 hours. The cells were then trypsinized and
harvested for fixation and analysis. Cells were fixed in ice-cold 70% ethanol
solution slowly while vortexing. After fixation, the fixed cells were stored at -20 oC
at least 24 hours before staining. Cells were washed once with PBS before being
permeabilized with 0.2%Triton X-100 in PBS for 10 minutes. Cells were then
washed once in PBS before being blocked in 1%FBS/PBS for 30 minutes. After
blocking cells were stained with 1 µg/ml anti-phospho H3 antibody (Upstate
Rabbit) for 1 hour at 4 oC. Cells were washed once with PBS before being
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stained with 1:1000 Secondary antibody 30 minutes at 4 oC in the dark. Cells
were washed once with PBS before resuspended in 500 µL of PBS/PI
(20µg/mL)/RNase (200µg/mL) solution, incubated for 15-20 minutes at 37 oC and
analyzed by LSRII flow cytometer (BD Pharmingen).

6.1.9 Southern blotting
Cells were collected by trypsinization, washed once in PBS and processed
for genomic DNA isolation. Genomic DNA was extracted as previously described
(de Lange et al., 1990). Genomic DNA was digested by a restriction enzymes
BamHI overnight before being run on a 0.7% agarose gel overnight. The gels
were depurinated with 0.25N HCl, denatured and neutralized using standard
Southern blotting protocol and transferred to nitrocellulose membrane. The
probes were synthesized by Klenow-based labeling using random hexamers and
α-32P-dCTP. Membranes were exposed to PhosphorImager screens and
quantified with ImageQuant software.

6.1.10 Quantitative reverse transcription-polymerase chain reaction (qRTPCR)
RNA was isolated using the RNeasyPlus extraction kit (Qiagen). cDNA
was synthesized using the SuperScript III First-Strand Synthesis System (Life
Technologies) and qRT-PCR was performed using the Platinum SYBR Green
qPCR SuperMix-UDG (Life Technologies) on an Applied Biosystems 7900HT
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Sequence Detection System. All steps were carried out as per the manufacturers’
instructions. Differences between samples calculated using QuantStudio
software (Applied Biosystems) using the ΔCT method and were normalized to
actin. Primers used for qRT-PCR are listed in 6.2.3.

6.1.11 Mutagenesis
Mouse

Fan1

cDNA

was

prepared

by

SuperScript

III

Reverse

Transcriptase (Thermo)-mediated cDNA synthesis using wild type mouse
embryonic fibroblasts (MEFs) RNA extract. The cDNA was cloned into
pENTR™/D-TOPO (Lifetechnologies). Mutagenesis was performed using the
QuikChange

Multi

Site-Directed

mutagenesis

kit

(Agilent)

as

per

the

manufacturer’s instructions using oligonucleotides listed in 6.2.2.

6.1.12 Cell lysates and immunoblotting
Cells were lysed in 2X Laemmli buffer (125 mM Tris-HCl, pH 6.8, 200 mM
DTT, 4% SDS, 20% glycerol, 0.02% bromophenol blue) at 106 cells per 100 μl,
sonicated at Amplitude 20 for 30 seconds (S-4000, MISONIX), and boiled for 5
minutes at 100 oC. The processed lysates were loaded at the equivalent of 1.5-2
105 cells per lane. Protein samples were separated by SDS-PAGE and blotted
onto PVDF blotting membranes (GE healthcare Life Sciences). Membranes were
blocked in 3% milk in t-BST (0.1% Tween-20 in 50mM Tris, 150mM NaCl, pH
7.6) for 1 hour at RT and incubated with primary antibody in 3% milk containing t-
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BST overnight at 4 oC or for 2-3 hours at RT. Membranes were washed 3 times in
t-BST, 10 minutes each and incubated with secondary antibody in t-BST for 1
hour at RT, and washed 3 times 10 minutes each with t-BST at RT. Blots were
developed with enhanced chemiluminescence (Perkin Elmer) on MultiImage II
FlourChem HD2 Imaging system (Alpha Innotech).

6.1.13 Immunofluorescence
Cells were grown on autoclaved-round coverslips. Cells were rinsed once
with PBS, before being fixed with 3.7% formaldehyde in PBS for 10 minutes at
RT and washed three times with PBS. Cells were blocked with PBG (0.2% (w/v)
cold water fish gelatin (Sigma), 0.5% (w/v) BSA (Sigma) in PBS) for 20 minutes
at RT, before being incubated with primary antibody diluted in PBG for 2 h at RT
or overnight at 4 oC. Afterwards, cells were washed 3 times with PBG at RT,
incubated with secondary antibody diluted 1:500 in PBG for 1 hour at RT, and
washed 2 times with PBG and 1 time with PBS. Coverslips were sealed onto
glass sides with mounting medium (VECTASHIELD with DAPI, Vector). Images
were captured with a Zeiss Axio Observer A1 microscope using Axiovision
software.

6.1.14 Chromosome breakage analysis
Cells were plated at around 75% confluency before being exposed to 50100 nM MMC 12 hours later for 24 hours. Afterwards, cells were arrested
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for 2 hours with 0.167 μg/mL of colcemid (EMD) (without media change). Cells
were harvested, incubated in 0.075 M KCl for 15 minutes at 37°C, and fixed in
freshly prepared methanol:glacial acidic acid (3:1). Metaphase spreads were
prepared by dropping cells onto pre-wetted microscope slides. Slides were airdried overnight at 40°C before staining with 6% Karyomax Giemsa (Life
Technologies) in Gurr buffer (Life Technologies) for 3 min. After rinsing with fresh
Gurr buffer and distilled water, slides were fully dried at room temperature and
scanned using the Metasystems Metafer. One-way ANOVA test was used to
determine the statistical significance. The quantification was blinded.

6.1.15 Histology
Tissues were harvested and fixed in 10% neutral buffered formalin for 20
hours at 4 °C. They were then washed twice with water before transferred to 70%
ethanol solution. The bone decalcification (femur/tibia), paraffin embedding,
sectioning and hematoxylin & eosin (H&E) staining were performed at the Center
for Comparative Medicine and Pathology at MSKCC. Quantification of nuclear
area in tissues was performed blinded to the genotype of the sample. Images
were captured at 40X objective on a Zeiss Axiovert 40 microscope and then
analyzed in ImageJ. The area (cross-sectional area) of at least 150 nuclei from
renal tubular epithelial cells or glomerular cells were measured and normalized to
the median nuclear area of each section. Data were then plotted and grouped
according to area.
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6.1.16 Fluorescent in situ hybridization (FISH)
FISH analysis was performed by the MSKCC Molecular Cytogenetics
Core. It is analyzed on a 5 μm-thick formalin fixed paraffin section using an inhouse 3-color probe for chromosomal regions: 12qA1.1, 16qA and 17qA1. The
probe mix consisted of the following BAC clones: 12qA1.1 (clones RP23-168O9,
RP23-54G4 & RP23-41E22; labeled with Green dUTP); 16qA (clones RP23290E4, RP23-356A24 & RP23-258J4; labeled with Red dUTP); and 17qA1
(clones RP23-73N16, RP23-354J18 & RP23-202G20; labeled with Orange
dUTP).

Probe

labeling,

hybridization,

post-hybridization

washing,

and

fluorescence detection were performed according to standard procedures. Slides
were scanned using a Zeiss Axioplan 2i epifluorescence microscope equipped
with a megapixel CCD camera (CV-M4+CL, JAI) controlled by Isis 5.5.9 imaging
software (MetaSystems Group Inc, Waltham, MA).

6.1.17 Generation of Fan1-deficient mouse strain
All of the animals were handled according to the Rockefeller University
institutional animal care and use committee (IACUC) protocols. Fan1 gene
targeting construct (Fan1tm1a(KOMP)Wtsi; MGI code: 4940765) was generated
by the Knockout Mouse Project KOMP. The construct was electroporated into
albino B6 mice-derived embryonic stem cells (ES) and the targeted ES cells were
injected into C57BL/6J blastocyst to generate chimeric animals by the Gene
Targeting and the Transgenic services at the Rockefeller University. Germline
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transmission of the targeted allele - Fan1(stop) was verified by the 5′ and 3′
probes on Southern blots (Figure 2.4) and used to generate Fan1lox from the
cross with FLPe deleter mouse stain (Jackson Labs). Fan1Δex3&4 allele was
generated from the cross between Fan1+/lox and E2a-Cre mice (Jackson Labs).
Fanca and Fancd2-deficient mice of 129SV background were obtained from
Marcus Grompe (Noll et al. 2002; Houghtaling et al. 2003). Slx4 and Mus81deficient mice of C57/Bl6 background were obtained from Paula Cohen
(Dendouga et al. 2005; Holloway et al. 2011). Aldh2- and Adh5- deficient mice of
C57/Bl6 background were obtained from KJ Patel (Langevin et al. 2011; Pontel
et al. 2015).

6.1.18 Genotyping
Genotyping was carried out by PCR on DNA isolated from mouse tail
samples digested overnight in 250 μl Direct PCR Lysis reagent (Yolk Sac,
Viagenbiotech supplemented with 0.4 mg/mL Proteinase K. PCR was performed
in 20 μl reaction containing 1.5 μl of DNA extract, 10x PCR buffer (Qiagen), 0.2
mM dNTP, 1% DMSO, 0.15 U of Taq polymerase (Qiagen) and 0.25/0.5 μM of
each individual primer. Genotyping primers are shown in 6.2.1.

6.1.19 Whole-animal MMC sensitivity
12 weeks old mice were injected intraperitoneally with a single dose of 10
mg of MMC per kg of body weight. Survival and body weight measurements were
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recorded daily. The percentage of survival was calculated according to the
Kaplan and Meier method (Kaplan and Meier 1958). Differences in survival
between the different genotypes were tested for significance by the Log-Rank
test. The hematopoietic analyses were done seven days following MMC
treatment in an independent cohort of mice. The blood was collected by cardiac
puncture and analyzed for complete blood count (CBC) and serum level of liver
and kidney marker analytes at the Center for Comparative Medicine and
Pathology at MSKCC. The bone marrow cells were collected for LSK analysis.

6.1.20 Alcohol administration in mice
Ethanol was provided to mice ad libitum in two different administration
schemes. For short-term exposure, water supply was replaced by a 15% Ethanol
solution for 5 days, followed by a 20% ethanol solution for another 5 days.
Alternatively, a 10% ethanol solution was provided to mice for 1 month in a longterm treatment scheme. To administer methanol, mice were gavage-fed with
methanol solution to a final dose of 80 mg/kg, 5 days per week for 4 weeks.
Following the treatments, mice were sacrificed for histological examination,
hematopoietic and genome instability analysis.

6.1.21 LSK analysis
Bone marrow cells were isolated from the femurs and tibiae of mice by
crushing the bone in FACs buffer (2% FBS in 1X PBS) followed by an additional

192

wash in FACs buffer, before being filtered through a 40-mm cell strainer. The
early progenitor cells (c-Kit+) were enriched by a 30-minute incubation with
CD117 (c-Kit) microbeads (Miltenyi Biotec) before passing through the LS
column (Miltentyl Biotec) placed under magnetic field. The column was washed
once with FACs buffer, followed by an elution outside of the magnetic field. The
c-Kit+ enriched cells were stained for 1 hour at 4 °C with the following antibodies
– PerCP-Cyanine5.5-conjugated lineage cocktail with antibodies anti-CD4
(Clone: RM4-5 eBioscience), CD3e (Clone: 145-2C11 eBioscience), Ly-6G/Gr-1
(RB6-8C5

eBioscience),

CD11b/Mac-1

(Clone:

M1/70

eBioscience),

CD45R/B220 (RA3-6B2 eBioscience), CD8a (Clone: 53-6.7 eBioscience), and
TER-119 (eBioscience), anti-c-Kit (APC, Clone: 2B8 eBioscience), anti-Sca-1
(BV421, Clone: D7 biolegend), anti-CD150 (SLAM) (PE, Clone: TC15-12F12.2
biolegend) and anti-CD34 (FITC, Clone: RAM34 eBioscience) and anti- CD16/32
(AF700, Clone: 93 ebioscience) (Frascoli et al. 2012). After one wash with FACs
buffer, the samples were resuspended in FACs buffer with 7-AAD (ebioscience)
before run on a LSRII flow cytometer (BD Pharmingen) and the data were
analyzed with the FlowJo software.

6.1.22 Long-term bone marrow reconstitution analysis
The bone marrow cells were isolated from donor animals (CD45.2) and
prepared as described in 6.1.21. To count the number of live nucleated cells, a
fraction of cells was treated with ACK lysing buffer (Life technologies) for 10
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minutes, followed by Trypan blue staining, and counted using a Countess Cell
counter (Life Technologies). 5x105 (primary transplant) or 2x106 (secondary
transplant) total bone marrow cells from femur/tibia of donor (CD45.2) mixed with
2.5x105 total bone marrow competitor cells (CD45.1) in PBS were transplanted to
the recipient animals (CD45.1) through retro-orbital injection. The recipient
animals were pre-conditioned with 2 doses of 450 cGy x-ray irradiation with a 3hour resting interval. The level of reconstitution efficiency was determined by the
ratio of CD45.2 to CD45.1 white blood cells using the following antibodies
cocktail – anti-Ter119 (APC eBioscience), anti-Gr-1 (PE eBioscience), anti-Mac1
(PB Biolegend), anti-B220 (BV521 Biolegend), anti-CD3 (APC-Cy7 Biolegend),
anti-CD45.1 (PE-Cy7 eBioscience), anti-CD45.2 (Pecp-Cy5.5 eBioscience), and
Propidium iodide (PI Sigma) and analyzed with before run on a LSRII flow
cytometer (BD Pharmingen) at 1, 2, or 4 months.

6.1.23 Micronuclei analysis of genome instability
The analysis was done as described in (Balmus et al., 2015). The blood
was collected through retro-orbital bleeding by heparinized capillary tubes
(Fisher) or cardiac puncture (if the animals were sacrificed) into the EDTA-coated
tubes (Greiner Bio-One). The blood was then resuspended in heparin solution
before fixed in cold methanol and stored directly at -80 oC for at least 12 hours.
After one wash with bicarbonate buffer, the cells were stained with anti-CD71
(FITC SouthernBiotech) in a solution containing 5 mg/mL RNase (Sigma). After 1
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wash with bicarbonate buffer, the cells were resuspended in bicarbonate buffer
containing 5 mg/mL PI and analyzed with a LSRII flow cytometer (BD
Pharmingen).

6.1.24 In vitro analysis of hematopoietic stem cell sensitivity to MMC
c-Kit+ enriched cells were isolated as described in 6.1. The cells were
then cultured in DMEM/F12 (Gibco) containing 100 U/mL penicillin, murine
recombinant cytokines including TPO (100 ng/mL Peprotech), SCF (100 ng/mL
Peprotech), FLT-3 (100 ng/mL Peprotech), IL-3 (20 ng/mL Peprotech), IL-6 (20
ng/mL Peprotech). 24 hours later, the MMC were added at different
concentrations (0 nM, 100 nM, 200 nM) and the cells were cultured for additional
48 hours. The cells were then harvested and washed once with FACs buffer
before stained for the LSK markers as described in 6.1.21.
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6.2 List of primers
6.2.1 Genotyping primers
Mouse genotyping primers
Genotype
Fan1+
Fan1Fancd2+
Fancd2Fanca+
FancaSlx4+
Slx4f3
Mus81+
Mus81Aldh2+
Aldh2Adh5+
Adh5-

Primer sequences
5’-AAGGTCTGTGGTCATCGTGTCAG-3’
5’-AAACGATCCCTGTCTGGCTGA-3’
5’-TGAGACAGCTCAACTGGCACT-3’
5’-AAACGATCCCTGTCTGGCTGA-3’
5’-TCAGCCTCACATGGAGTTTAACG-3’
5’-AA TTCGCCAATGACAAGACGC-3’
5’-TCAGCCTCACATGGAGTTTAACG-3’
5’-CAGGGATGAAAGGGTCTTACGC-3’
5’-TTCCTTCAAAGCTGCTGGGG-3’
5’-CAGTGACATCTTCCTTCCTAACTCC-3’
5’- TTCCTTCAAAGCTGCTGGGG-3’
5’- GGTGAACGTTACAGAAAAGCAGGCT3’
5’-CACTGAGCCATCTCACCAGC-3’
5’-GGAGCCCAGTCTGGGACTCTG-3’
5’-CACTGAGCCATCTCACCAGC-3’
5’-TCGTGGTATCGTTATGCGCC-3’
5’-CTAGCCGCTTGCGTTCCACAATGT-3’
5’-GGAGCTAAGGCCTAGCGAGTACAG-3’
5’-GGTGTGGCCCTGATGGAAGAG-3’
5’-GGAGCTAAGGCCTAGCGAGTACAG-3’
5’-AAACTTTGCACACACTGTCCC-3’
5’-CCCAGATCCAACTGTTAGGAATAC-3’
5’-AAACTTTGCACACACTGTCCC-3’
5’-GCTTCACTGAGTCTCTGGCATCTC-3’
5’-TCAAGAGGTGAGGCTACAAGTT-3’
5’-GGCATGTCTTCATTTAGCTCAC-3’
5’-CCTGCCGAGAAAGTATCCATCATG-3’
5’-CCAAGCTCTTCAGCAATATCACG-3’
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Amplicon size
(bp)
292
543
300
550
350
600
475
298
418
380
212
441
200
374

6.2.2 Mutagenesis
Mutagenesis primers
Mutation

Primer sequences

FAN1
C44A/C47A

5’-CAGTGCACCACCTGCTAAACTTGCAGCT
TCAACTGCTCATAAAATGGTGCCCA-3’

FAN1 L480P

5’-TCTGCTCCTGAGCCGAAAGCCCTGGCC-3’

FAN1 D963A

5’-GGGGCCTCCCAGCCTTGGTGGTGTG-3’

6.2.3 RT-PCR
RT-PCR primers
Gene
Mouse Fan1
Mouse Snm1a
Mouse Actin

Primer sequences
5’-CACAGTCCTGTGTTCTGTGGA-3’
5’-TCAAAGCCACTCTGCCTGTA-3’
5’-GCAAAGTCCACACACTGTTCC-3’
5’-CTGCTGTGACGGGAAGGTAT-3'
5’-CTAAGGCCAACCGTGAAAAG-3’
5’-ACCAGAGGCATACAGGGACA-3’

6.2.4 List of shRNAs
shRNA target sequences
shRNA

Target sequences

Mouse Snm1a.1

5’-TGACTCTTTTCTGCTTCT-3’

Mouse Snm1a.2

5’-CAGAATCTGTTGAAAAATCA-3’

Mouse Snm1a.3

5’-CATGTCCGTTCTATAAGAGA-3’

Human
DNA-PKcs.1

5’- AAAGCATGTTTCTTTAAATAA-3’
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Human
DNA-PKcs.2
Human
DNA-PKcs.3

5’-CCCGGTAAAGATCCTAATTCT-3’
5’-CCACCATGGATGTGTTTGTCA-3’

Human Ku70.1

5’-AACGGATCTGACTACTCACTC-3’

Human Ku70.2

5’-ACAGGTTAAAGCTGAAGCTCA-3’

Human Ku70.3

5’-CAGGGAAAGTTACCAAGAGAA-3’

Human Ku80.1

5’-CCAGCTGGATATTATAATTCAT-3’

Human Ku80.2

5’-CCCCGCTGAGGTGACAACAAA-3’

Human Ku80.3

5’-CAAGAGAGAAAGTTTCGTTAT-3’

Human 53BP1.1

5’-CAAGGATGTACATGTTGTAAA-3’

Human 53BP1.2

5’-AAAGGAGAAGAGGAGAAAGAA-3’

Human 53BP1.3

5’-AACGATTATGTTTCTCACTAA-3’

Human FANCA.1

5’-CCTGCAGAGAATGCTGATTTT-3’

Human FANCA.2

5’-AACAGTATGTTCTCCCGTCTT-3’

6.2.5 List of sgRNAs
sgRNA target sequences
Gene

Target sequences

Mouse Snm1a

5’-CGAAGGTGCGCCCTGTTTAT-3’

Human FAN1

5’-CGTTCAAGTGGATCCAGGG-3’
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6.3 List of Antibodies
Antigen

ID

Source

Uses

mFAN1

S101D

John Rouse lab

WB

mFANCD2

EPR2302

Abcam

WB

HA

MMS-101R

Covance

WB, IF

hFAN1

AP394

In-house

WB

GFP

Clones 7.1 and
13.1

Roche

WB, IF

γH2AX

JBW301/05-636

Upstate

WB, IF

H2AX

A300-082A

Bethyl

WB

hDNA-PKcs

Clone: 25-4

Fisher

WB

h53BP1

NB100-304

Novus

WB, IF

hKu70

N3H10

NeoMarkers

WB

hKu80

C-ter Ku80

Lisa Postow
Funabiki lab

WB

hFANCA

A301-980A

Bethyl

WB

hFANCI

AP583

In-house

WB

hFANCD2

NB100-182

Novus

WB, IF

hXPF/ERCC4

Bethyl

A301-315A

WB

hMUS81

M1445

Sigma

WB

α tubulin

T9026

Sigma

WB
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6.4 List of cell lines
Cell lines

Organism

BJ

Human, Fibroblasts

A1170-22 (KIN patients)

Human, Fibroblasts

A4466 (KIN patients)

Human, Lymphocytes

A4486 (KIN patients)

Human, Lymphocytes

A4385 (KIN patients)

Human, Lymphocytes

RA3087 (FA-A patients)

Human, Fibroblasts

RA2645 (FA-D2 patients)

Human, Fibroblasts

RA3331 (FA-P/SLX4 patients)

Human, Fibroblasts

RA3087 pcwCAS9

Human, Fibroblasts

RA2645 pcwCAS9

Human, Fibroblasts

RA3087sgFAN1

Human, Fibroblasts

RA2645sgFAN1

Human, Fibroblasts

WT HCT 116

Human, Colorectal carcinoma

LIG4+/- HCT 116

Human, Colorectal carcinoma

LIG4-/- HCT 116

Human, Colorectal carcinoma

LIG3-/+mtLIG3 HCT 116
LIG3-/+mtLIG3+ncLIG3
HCT 116
LIG3-/+mtLIG3+ncDBRCTLIG3
HCT 116

Human, Colorectal carcinoma
Human, Colorectal carcinoma

Human, Colorectal carcinoma
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Cell lines

Organism

Fan1+/+

Mouse, E13.5 MEFs

Fan1+/-

Mouse, E13.5 MEFs

Fan1-/-

Mouse, E13.5 MEFs

Fancd2-/-

Mouse, E13.5 MEFs

Fan1-/-Fancd2-/-

Mouse, E13.5 MEFs

Fanca-/-

Mouse, E13.5 MEFs

Fan1-/-Fanca-/-

Mouse, E13.5 MEFs

Fan1-/-sgSnm1a.6

Mouse, E13.5 MEFs

Slx4f3/f3

Mouse, E13.5 MEFs

Fan1-/-Slx4f3/f3

Mouse, E13.5 MEFs

Mus81-/-

Mouse, E13.5 MEFs

Fan1-/-Mus81-/-

Mouse, E13.5 MEFs
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